

REVIEW

[View Article Online](#)
[View Journal](#) | [View Issue](#)Cite this: *Mater. Adv.*, 2023,
4, 6064Natural cationic polymer-derived injectable
hydrogels for targeted chemotherapySabya Sachi Das,^{†*a} Devanshi Sharma,^{†bc} Balaga Venkata Krishna Rao,^{†d}
Mandeep Kumar Arora,^{†a} Janne Ruokolainen,^e Mukesh Dhanka,^b Hemant Singh^b
and Kavindra Kumar Kesari^{†*ef}

Injectable hydrogels have the potential to revolutionize therapeutics. Therapeutic hydrogels exhibit distinctive physicochemical properties, including flexible porous structure, binding affinity for biological fluids, porous structural configuration, higher water content, high flexibility, biodegradability, and biocompatibility. These technologies have had tremendous clinical implications, specifically for the site-specific and sustained delivery of chemotherapeutic drugs. Drug-encapsulated injectable hydrogels showcase significant superiority over conventional therapeutics, such as minimized adverse effects, enhanced therapeutic efficacy, augmented pharmacological profile, and superior patient compliance. Conventional approaches mainly include intravenous chemotherapy, which can potentially cause adverse effects such as myelosuppression, nephro- or hepatic dysfunction, and neurotoxicity. The injectable hydrogel is a potent approach to overcome these impediments by releasing the chemotherapeutic drugs at specific tumor sites after topical administration. Moreover, the therapeutic efficiency of cancer immunotherapy is majorly dependent upon the tumor microenvironment, which can be targeted with chemotherapeutic drug-loaded injectable hydrogels for improved cancer therapy. In addition, natural cationic polymers such as chitosan, cyclodextrins, gelatin, cellulose, dextran, and others have received substantial attention from investigators in drug delivery due to their easy obtainability, high encapsulation efficiency, improved bioavailability, sustained drug release properties, biodegradability, and biocompatibility. This review summarizes the mainstream approaches for synthesizing injectable hydrogels and the biological properties of different natural cationic polymers. We have also focused on the notable studies of cationic polymers used definitively to fabricate hydrogel-mediated systems for anticancer drug delivery. Further, the therapeutic approaches, molecular insights, pharmacological actions, and clinical significance have been discussed.

Received 30th July 2023,
Accepted 18th October 2023

DOI: 10.1039/d3ma00484h

rsc.li/materials-advances

1. Introduction

Cancer is one of the leading causes of social, clinical, and economic burden compared to all other various human diseases. With 18 million newly reported cancer cases, the most recurrently occurring cancers are lung, breast, and prostate

cancers.¹ Cancer's increasing frequency, prevalence, and morbidity indicate the burden of malignant diseases for a prolonged time.² Breakthrough technological and scientific advancements in targeted delivery for cancer treatment hold the potential for revolutionizing cancer care worldwide.³ Environmental and lifestyle factors are the leading causes of cancer. Early identification of various causes of cancer and the proposal of a multi-stage model of cancer by epidemiologists have paved the way for extraordinary advances in the treatment and identification of cancers through various cellular and molecular approaches.⁴ Long suspected risks which are minor in nature are now being estimated more precisely due to various advancements in theranostics and drug delivery approaches. The impact of the COVID-19 pandemic across various regions around the globe has resulted in delay in terms of diagnosis and treatment thereby resulting in an overall increase in mortality caused by cancer.^{1,5}

Elementary results of clinical studies suggest combining combinational therapies with the standard conventional

^a School of Pharmaceutical and Population Health Informatics, DIT University, Dehradun-248009, Uttarakhand, India. E-mail: ss.das@dituniversity.edu.in^b Discipline of Biological Engineering, Indian Institute of Technology Gandhinagar, Gandhinagar, Palaj, 382355, Gujarat, India^c Institute of Science, Nirma University, S G Highway, Ahmedabad-382481, Gujarat, India^d School of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur-302017, Rajasthan, India^e Department of Applied Physics, School of Science, Aalto University, 00076 Espoo, Finland. E-mail: kavindra.kesari@aalto.fi^f Research and Development Cell, Lovely Professional University, Phagwara, Punjab, India[†] These authors contributed equally.

therapies for cancer treatment. The mode of delivery used during combinational therapy can enhance treatment efficacy and influence disease progression due to prolonged time.⁶ Research has suggested using molecular and immunological factors to inhibit cancer progression at later stages, which is effective.⁷ Studies have demonstrated that cancer chemotherapy usually causes nausea and vomiting. However, present treatments to regulate and monitor acute chemotherapy-induced nausea and vomiting (CINV) are practically effective in most patients, but deferred CINV is more vital and challenging.⁸ The consolidative perception associated with the various hallmarks of cancer has helped to refine the

complexities of cancer and re-occurrence. The understanding can lead to the establishment of the mechanisms of cancer development and malignant progression, and to the development of effective cancer therapies with negligible toxicity possibilities.^{9,10} Apart from this, one of the most critical limitations related to chemotherapy is their inability to sensitivity to currently accessible chemotherapeutic drugs and occurrence of drug resistance. In addition, precise information and understanding of various mechanisms associated with chemotherapeutic effects is highly needed to establish significant findings or outcomes.¹¹



Sabya Sachi Das

Dr. Sabya Sachi Das joined as an Assistant Professor in the School of Pharmaceutical and Population Health Informatics, DIT University, Uttarakhand, India, after completing his PhD from Birla Institute of Technology, Jharkhand, India. His area of research mainly includes solid dispersions, polymer/lipid/metallic-based nanoparticles, nano-phytotherapeutics, and targeted nano-biomaterials for diverse theranostic applications.

He has published scientific articles (>30) in peer-reviewed international journals and published book chapters (>25) with an H-index of 15 (Google Scholar). He is a reviewer (>20) for various peer-reviewed international journals. Additionally, he has presented (>10) and participated (>35) in national and international scientific research platforms.



Mandeep Kumar Arora

Dr. Mandeep Kumar Arora is an Associate Professor in the School of Pharmaceutical and Population Health Informatics, DIT University, Uttarakhand, India. He received his PhD from Swami Vivekanand Subharti University, Meerut, Uttar Pradesh, India. His research area mainly focuses on vascular pharmacology, pharmacovigilance, metabolic disorders, and nanomedicine. He has published scientific articles (>35) in peer-reviewed international journals

and books. He has also published 3 books and 11 Indian Patents (1 in Tech Transfer Process, 2 Granted, 8 Published) with an H-index of 10 (Google Scholar).



Janne Ruokolainen

Dr. Janne Ruokolainen is a Professor in the Department of Applied Physics, Aalto University, Espoo, Finland. He gained his PhD (Tech) in Materials Physics from Helsinki University of Technology and Docentship in polymer physics and soft materials microscopy. His current research activities focus on the characterization of molecular bioactive compounds extracted from plant species in neurodegenerative disease

treatment. He has published over 300 scientific papers in peer-reviewed journals (H-index 69: Google Scholar as of November 2023). His awards and honours include IUPAC Prize for Young Chemists-Honourable Mention Award (2001), Young Scientist Award by the Foundation of Technology (2002) and many others.



Mukesh Dhanka

Dr. Mukesh Dhanka is an Assistant Professor at the Biological Sciences and Engineering Department, IIT, Gandhinagar, India. He earned his PhD in Biomedical Engineering from the Indian Institute of Technology Bombay, and completed postdoctoral studies at the Institute for Stem Cell Science and Regenerative Medicine (inStem), Bangalore, India. His research focuses on developing innovative drug-

delivery technologies to treat a wide range of significant clinical problems, including chronic wounds, cancer, autoimmune disorders, joint disorders (inflammatory and degenerative conditions), bacterial infections, and others.



Conventional therapies for cancer, such as chemotherapy, radiation therapy, and surgery, have several side effects. Thus, various targeted and non-conventional ways are being researched to treat cancer.^{7,12} One of them is the use of exosomes. Exosomes can be categorized as diagnostic markers and therapeutic agents in cancer therapy due to their ability to have high biocompatibility, stability, immunogenicity, pharmacokinetics, biodistribution, and a cellular uptake mechanism. Due to their size and heterogeneity, exosomal delivery is still being researched.¹³ Certain limitations of various conventional therapies, like immunosuppression, modulation of tumor microenvironment's expression of tumor antigens, *etc.*, are still being researched, leading to surpassing these limitations.¹⁴ Studies have shown that chemotherapy has demonstrated disruption of the various suppressive pathways and lymphodepletion post administration of chemotherapy.¹⁵

Even injectable biomaterials have several challenges for the design of optimal therapies, including optimization of the material form, method of injection, and the mechanisms of action of the same.^{16,17} Injectable hydrogels with desired response to pH and self-healing ability can be used for anti-cancer drug-delivery.¹⁸ Making a pH-responsive injectable hydrogel is crucial for efficient drug release in the targeted acidic environment. The self-healing property of an injectable hydrogel can prolong the life during the implantation and provide the benefit of minimally invasive surgery.¹⁹ In addition, it has been reported that the functionalized-fluorescent nanoparticle conjugated hydrogel systems can simultaneously exhibit fluorescence properties and can be tagged with therapeutics to accomplish their therapeutic efficacy, leading to improved

theranostic applications.²⁰ The intelligent hydrogel drug delivery system that released doxorubicin for hepatocellular carcinoma enhanced anti-cancer response generation. Injectable hydrogel's self-healing ability can be confirmed by forming Schiff's base.²¹ In addition, recent studies have reported that fluorescent nanoparticle conjugated hydrogels have been extensively explored for drug delivery, biosensing and imaging applications.²⁰

As an alternative approach, injectable hydrogels for localized chemotherapy have shown diminishing effects of systemic chemotherapy and provide the sustained release of chemotherapeutics at the targeted tumor site.²² Injectable hydrogels formed *in situ* include thermosensitive hydrogels, photosensitive hydrogels, active targeting hydrogels, *etc.* the systemic administration of various chemotherapeutics is dose limited and shows off-target toxicity. Smart injectable hydrogel delivery systems for localized chemotherapeutic administration are promising ways to combat the side effects and toxicity.²³ Injectable hydrogels possess a sol-gel transition phase dependent on the concentration of the polymer and crosslinker used. This makes them physically responsive to various body-specific factors like pH and temperature. Synthetic and natural polymers have been studied based on their structure, chemical bonding, and mechanical properties for making controlled drug release systems to enhance therapeutic efficacy.²³

The injectable hydrogel's efficacy greatly depends on the polymeric properties and what kind of anti-cancer drugs are being used. Thus, in this review, we have summarized the method of preparation and characterization studies essential for hydrogels. Further, we have discussed the therapeutic potential of various natural cationic polymeric injectable hydrogels to deliver chemotherapeutic agents in cancer therapy effectively. Finally, we have listed various reported or ongoing clinical/pre-clinical studies associated with anticancer drug-encapsulated polymeric injectable hydrogels for treating multiple cancers.

2. Injectable hydrogels: methods of preparation and characterization

Owing to their high water content and mechanical strength as in the case of natural tissues, hydrogels have emerged as promising sources for biomedical applications.²⁴ Hydrogels can be formed as an injectable material to fulfill the criteria of non-invasiveness, thereby significantly decreasing the costs of surgery and recovery.²⁵ Self-healing hydrogels in liquid form are injected inside the body and rapidly form a gel eliminating the risks of the crosslinker used. Injectable hydrogels can surpass phase-1 of drug metabolism.²⁶ Specific requirements should be considered while forming the injectable hydrogel for biomedical/clinical applications, such as viscosity, mechanical properties, biocompatibility, *etc.*²⁶ The two widely used approaches for the crosslinking of polymers include physical cross-linking and chemical cross-linking for the application of



Kavindra Kumar Kesari

Dr. Kavindra Kumar Kesari is a Senior Researcher in the Department of Applied Physics, Aalto University and University of Helsinki, Finland. He obtained a Doctoral degree in Biotechnology and he received Junior and Senior Research fellowships during his Doctoral studies at Jawaharlal Nehru University, New Delhi, India. He is actively involved in material-based cell and cancer biology research. He has published over

150 papers (H-index 37: Google Scholar as of November 2023) in reputed scientific journals, 30 book chapters, and 7 books, and has presented over 40 papers at national and international scientific meetings. He has been acting as Commissioner at the ICBE EMF, USA, since 2021 and has been an Honorary Faculty Member for NGCEF, New South Wales, Australia, since 2020. He received four times Young Scientist Award for the outstanding contribution in research.





Fig. 1 Various strategies for the synthesis of various hydrogel-based systems.

drug delivery (Fig. 1). However, many laboratories that developed injectable hydrogels still face significant challenges regarding translation into clinical use.²⁵ Hydrogels are attractive delivery systems for localized and targeted therapy due to their sustained delivery. In addition, unlike active and passive targeting techniques, hydrogels work well regardless of tumor blood supply and microvasculature.^{27,28} Moreover, they can enhance the physical stability of the therapeutic drugs inhibiting drug precipitation.²⁹

In the recent era, *in situ* stimuli-responsive hydrogel-based systems, also known as smart hydrogels, have shown immense importance for delivering chemotherapeutic agents with no or negligible systemic toxicity.¹⁹ These smart hydrogels exhibit properties such as superior injectability, biocompatibility, and sensitivity to various stimuli, including pH, heat, enzyme, light, electric potential, and magnetic field (Fig. 2a). Interestingly, the behavior of drug release is well regulated in several types of smart hydrogels as a response to different stimuli such as enzymes, electric impulses, magnetic field, and glutathione (Fig. 2b). In particular, the pH-responsive hydrogel exhibits enhanced antitumor activity by enhancing the acidity within the tumor microenvironment and again neutralizing to normal pH leading to suppression of tumor growth (Fig. 2c).³⁰

The several mechanisms currently used for preparing injectable hydrogels are physical cross-linking, chemical cross-linking, ionic cross-linking, *i.e.*, self-assembly, and enzyme-initiated cross-linking.²⁵ Injectable hydrogels that are physically cross-linked have the gelation triggered by temperature, pH, *etc.* However, it is a one-phase system; during delivery, there is a significant chance of a higher burst release of drug

from the hydrogel.³¹ Chemical cross-linking results in enhanced elasticity properties but has the drawback of toxic precursors used for cross-linking.²⁵ Aldehyde chemistry used during chemical cross-linking lacks specificity even if paired cross-linking occurs.²⁵ Enzyme-initiated crosslinking is highly specific and depends mainly on the enzyme concentration.²⁵ Injectable tissue engineering constructs are well-structured cell carriers that showcase the potential of the minimally invasive techniques of delivery.²⁵ In physically cross-linked injectable hydrogels, the gelation occurs after the injection, and the most significant aspect to drive the gelation is the body temperature.³² Hence, the crosslinking properties of the polymeric precursors through physical or chemical medium and their response to external stimuli such as temperature and ionic concentration control injectable hydrogel formation.²⁶ The self-healing behavior of the injectable hydrogel is governed by non-covalent interactions and dynamic covalent bonds or sometimes both.³³ Hydrogels that show shear-thinning can also be categorized as injectable hydrogels due to the adequate control of gelation kinetics.³⁴

2.1. Physical cross-linking approaches

The safest crosslinking method showcasing non-toxic behavior, high biocompatibility, and intense self-healing ability is through physical non-covalent polymerization by the bonds.³⁵ The structure formed by the physical cross-linking method depends on the type of interaction between the molecules.³⁵ Several types of interactions can occur, *i.e.* ionic interaction (based on the negative charges present in different functional groups or *via* metal-ligand interaction),³⁶ hydrogen bond





Fig. 2 (a) Schematic phase transition of representative hydrogels: (i) temperature-responsive hydrogel; (ii) pH-responsive hydrogel; (iii) ionic strength-responsive hydrogel. (b) Schematic presentation of drug release from representative smart hydrogels upon various stimuli. (c) *In situ* pH-responsive hydrogel alleviates the tumor's acidic microenvironment and inhibits tumor growth. Reproduced from ref. 30 with permission from MDPI, copyright 2022.

formation resulting in enhanced self-recovery property of the hydrogel and high efficacy in terms of self-repair,³⁷ and crystallization (*via* freeze-thawing), hydrophobic interactions (mainly for the hydrophobic water-soluble polymers) and lastly through protein interaction and conjugation³⁸ where the proteins are synthesized rationally, *e.g.* T4 lysozyme mutant which has several free amine groups on the surface. These customized covalent interactions can increase the strength of the hydrogel network, constitutively exhibiting specific binding affinity for different metal ions such as zinc and magnesium.³⁹ Cross-linking through UV (ultraviolet) irradiation has also been extensively explored for the various kinds of hydrogel.⁴⁰

2.2. Chemical cross-linking approaches

The structural linkages formed through chemical cross-linking are stronger than the physically cross-linked hydrogels. The cross-linking is induced through the induction of free radical polymerization, a “click” reaction known as the Diels–Alder reaction, a reaction involving the formation of Schiff base, a Michael type-addition reaction, and the formation of oximes.⁴¹

One of the significant advantages of using the chemical cross-linking method is its controllable degradation behavior.⁴² Enzymatic cross-linking has paved the way for actively manipulating the kinetics of the *in situ* gel formation by varying the concentration of enzymes which results in covalent solid bond formation and interaction, thereby causing gelation rapidly.⁴¹ Transglutaminase has been widely used as the enzymatic cross-linker for several injectable hydrogels due to its formation of amide linkages.⁴³

The widely recognized click chemistry has proven advantageous due to high yield even under milder conditions, high selectivity and specificity, and less by-product formation.⁴⁴ Cross-linking through the Diels–Alder reaction, which involves cycloaddition between a dienophile and a diene, is highly selective in nature but has the significant advantage of the reaction being a one-step process without using any catalysts, initiators, or coupling reagents; however, it requires the modification of the hydrogel polymers with furan derivatives or furan alone.⁴⁵ Another reaction involving click-chemistry that results in the formation of Schiff base occurs between amino



and aldehyde groups that generate imine linkage under physiological conditions. This reaction helps enhance the hydrogel's self-healing capacity, and the self-healing behavior is highly dependent on the pH of the surrounding medium.⁴⁶

Hydrogels cross-linked by oximes and through Michael's addition reaction result in self-healing hydrogels with good mechanical strength. The oxime bond formation exhibits elevated hydrolytic stability. Oxime crosslinking occurs between the hydroxylamine/aminooxy group and a ketone/aldehyde, group showcasing high specificity, and also with few other functional groups.⁴⁷ Michael's addition reaction tends to be a more simplistic response involving nucleophiles and electrophilic olefins/alkynes in an activated form, which are added across C–C multiple bonds. The advantage of the Michael addition reaction is the favourable reaction rates and the reaction occurring even under mild conditions.⁴⁸

As the functionality and properties of hydrogels depend on the density of cross-linking, polymeric composition, strength, internal structure, and the water holding capacity, these parameters can be judged by the physicochemical and mechanochemical characterization to provide both quantitative and qualitative data.⁴⁹ Hydrogel properties such as mechanical strength, viscosity, swelling, and elasticity highly depend on the polymer chain's dimensions, the fibers' orientation and the chemical bonds present.⁵⁰ The characterization methods are based on rheology, scattering, microscopy, composition, and strength measurements.⁵¹ The microscopy methods successfully provide real-space images of the hydrogel structure. Hydrogels are broadly characterized in two ways, *i.e.*, dried (freeze-dried or in the air) or hydrated (according to the water content present).⁵² Various kinds of hydrogels require different instrumental settings.⁵² For mechanochemical characterization, rheology is the most appropriate method because it is sensitive, quick, and has a small sample size requirement and the potential to reveal the degree to which the cross-linking has been done, homogeneity/heterogeneity of structure, *etc.*⁵³ Rheology involves the characterization of hydrogels *via* small-amplitude oscillatory shear (SAOS).

Physicochemical characterization involves phase analysis through XRD, and for chemical description, FTIR is done. For morphological analysis and to view the microstructure and pore size, characterization of the lyophilized hydrogel samples is done through FESEM.⁵⁴ Density measurement is also an important factor for the characterization of hydrogels, which is estimated by attaining integrated function of density. However, it requires a desiccator before analysis.⁵⁵ DLS-zeta potential is used to determine the surface charge, thereby determining the stability of the nano-formulation.⁵⁶ Each type of technique requires a precise methodology for sample preparation resulting in accurate and efficient qualitative data generation.⁵⁷

3. Natural cationic polymers: preparation methods and anticancer mechanism

Cationic polymer-mediated hydrogels are synthesized using cationic monomers and/or polymers isolated from natural,

synthetic, and semi-synthetic sources. In the last few decades, such biomaterials have gained much interest due to diverse therapeutics and biomedical applications. These hydrogel systems are biocompatible, biodegradable, and bio-responsive, accelerate tissue regeneration, exhibit antimicrobial activity, and enable controlled release of drugs/biomolecules, leading to their high applicability in therapeutics.⁵⁸ The pH of the hydrogel plays a crucial role in deciding if the behavior of the hydrogel would be hydrophobic or hydrophilic. Also, charged groups over the polymeric backbone affect the osmotic equilibrium between the hydrogel and the adjacent medium.⁵⁹ In addition, cellular adhesion enhancement and heparin immobilization are significantly affected by the cationic hydrogels.⁵⁸ Natural cationic polymers are obtained from natural biodegradable sources exhibiting low toxicity and immunogenicity. Modifying external reactive sites can alter most of their physicochemical properties.^{58,60} This aids in their wide biomedical applications, including drug and gene delivery and other tissue engineering applications. Cationic polymeric hydrogels are composed of various cationic polymers; however, the most used naturally occurring cationic polymers include chitosan, dextran, cellulose, and gelatin alone or in combination.

Chitosan, a cationic polymer, comprises randomly distributed D-glucosamine and N-acetyl glucosamine units (Fig. 3a). It is a potential carrier for drug delivery applications due to its biodegradability, biocompatibility, and mucoadhesive properties.⁶² Cationic chitosan polymer particles can be obtained by various methods, including emulsion crosslinking,⁶³ polyelectrolyte complexation,⁶⁴ and the most widely used ionic gelation method.⁶⁵ Studies have shown that chitosan strongly attracts the sialic acid (negatively charged) residues over the red blood cells, leading to severe hemagglutination.⁶⁶ Additionally, chitosan has been demonstrated to augment the function of fibroblasts, macrophages, and leukocytes, leading to significant improvement in granulation and tissue regeneration.⁶⁰ Lu *et al.* prepared a lanthanum-doped chitosan hydrogel. When evaluated on mouse melanoma cells (B-16) and skin fibroblast cells (L929), it prevented the proliferation of B-16 melanoma cells and further reduced the accumulation of toxic side effects for L929 skin fibroblast cells.⁶⁷ Similarly, in another study by Highton *et al.*, the chitosan hydrogel was evaluated on CD8+ T cells in a mouse model and it was found that vaccination with the chitosan hydrogel was equally effective as dendritic cell vaccination in terms of tumor protection.⁶⁸

Cyclodextrins are a class of cyclic oligosaccharides formed by D-(+)-glucopyranoses linked by a 1,4- α -glucosidic bond (Fig. 3b). Industrially they are produced *via* amylose zymolysis in the presence of glucose transferase. α -, β -, γ -forms of cyclodextrins are the most common forms, and they mainly differ owing to the presence of glucopyranose units. α -, β -, γ -forms contain 6, 7, and 8 glucopyranose units, respectively.⁶⁹ Although they differ in their internal diameter, owing to stable intramolecular hydrogen bonding, they have the same depth of 7.9 Å.

Cellulose, the main constituent of the plant cell wall, is one of the most abundant organic materials. It consists of ringed β -1,4-D-glucan molecules that are arranged linearly (Fig. 3c).






Fig. 3 Chemical configurations of (a) chitosan, (b) cyclodextrin/s, (c) cellulose, (d) acetalated dextran, and (e) gelatin. An image of gelatin reproduced from ref. 61 with permission from MDPI, copyright 2021.

Although numerous preparative strategies exist, enzymatic hydrolysis⁷⁰ and acid hydrolysis⁷¹ are the most widely used. The anticancer effects of doxorubicin-loaded carboxymethylcellulose hydrogel was reported against HEK 293T cells, and A375 melanoma cancer cells with improved cytotoxicity.⁷²

Gelatin, a biodegradable and inexpensive polymer of natural origin, is obtained from collagen and has wide biomedical applications.^{73–75} The cationic property of gelatin is inherited by the arginine and lysine residues (Fig. 3d). Along with lysine and arginine, it consists of 18 amino acids dispersed in a non-uniform manner. Gelatin is obtained from a variety of methods, including green extraction technologies,⁶¹ emulsification solvent evaporation,⁷⁶ coacervation phase separation,⁷⁷ reverse phase microemulsion,⁷⁷ and desolvation.⁷⁸

Dextran is a hydrophilic homopolysaccharide of glucose (Fig. 3e) and possesses exceptional properties such as biodegradability, bioavailability, and hydrophilicity.⁷⁹ Doxorubicin-loaded dextran composite hydrogels substantially suppressed tumor cells when evaluated for skin cancer on mouse myoblast cells (C2C12) and human liver cells (HL7702).⁸⁰

3.1. Cationic polymers targeting hallmarks of cancer

Various physiological events regulate the divergence, apoptosis, proliferation, and cell arrest which further control homeostasis

and activities of cells/tissues. Any irregularity amongst these consecutive events changes the proportion between cell death, cell variation, and proliferation leading to the formation of carcinogenic cells and/or tumors.^{81,82} Furthermore, various macromolecular transport pathways within the tumor vessels appear through open gaps, vesicular organelles, and apertures. The physicochemical and physiological properties of the interstitium and the physicochemical characteristics of the chemotherapeutics play a crucial role in governing the transportation of anticancer drugs.⁸³ Thus, successful delivery of a chemotherapeutic drug to cancer or tumor cells *in vivo* can be attained by overcoming the various physiological barriers of the tumor microenvironment at the cellular level. The cationic polymeric hydrogel systems have shown immense progress as carriers for chemotherapeutic drugs at targeted carcinogenic sites with negligible cytotoxicity.^{84,85}

3.1.1. Chemoimmunotherapy for cancer targeting. Cancer chemoimmunotherapy is a treatment that combines chemotherapy and immunotherapy. Chemotherapy generally includes administering traditional cytotoxic drugs and novel therapeutic agents targeting novel molecular targets. In contrast, immunotherapy targets and combats malignant cells *via* the individual's immune system. This includes using cancer vaccines and cytokines, along with exploring techniques such






Fig. 4 Various biological targets of chemo-immunotherapeutic agents during the cancer immune process. Chemotherapeutics assist in immunomodulatory effects mainly through (A) inducing immunogenic cell death (ICD); (B) inducing immune activation; and (C) triggering reduction of suppressor cells. *Int. J. Nanomed.*, 2022, **17**, 5209–5227 ref. 88. Originally published by and used with permission from Dove Medical Press Ltd.

as utilizing immune checkpoint inhibitors and adoptive cell therapy.⁸⁶ The cancer immune cycle refers to the cyclical process of the immune response regulated by immune signals that are either stimulatory or inhibitory. Significant steps in these cyclic processes include tumour-specific T cell activation, multiplication, migration, and infiltration into the tumor site and antigen presentation by antigen-presenting cells (APCs), further T cell recognition, and eventually killing tumor cells.⁸⁷

Immunotherapy enhances the antitumor immune response by activating or suppressing immune system components, resulting in a highly active long-lasting T-cell response against the tumor and forming a stable immune memory. However, immunosuppressive TME limits the clinical application of immunotherapy. For instance, suppressive molecule expressions are affected by cancer cells, which can compromise immune system surveillance, further reducing the effectiveness of immunotherapeutic methods and eventually making monotherapy ineffective against tumor cells.

Preclinical evidence suggests that chemotherapeutic and immunotherapeutic agents work in tandem to modulate various targets' immune reactions throughout the cancer immune cycle by stimulating or suppressing different cellular and molecular pathways (Fig. 4).⁸⁸ Combination therapy can potentially increase antitumor activity, promoting autoimmune system rebuilding while minimizing toxicity and long-term effects. Cancer vaccines, adoptive cell therapies, immune-checkpoint blockade, and cytokine methods are some of the cancer

immunotherapy approaches that have been successfully developed.⁸⁹ Chemotherapy continues to be the most effective option in cancer treatment. Owing to the TME's synergistic effects, it has been demonstrated that chemotherapy and immunotherapy, when combined, are potentially helpful in cancer therapy.⁹⁰ Simply using chemotherapy and immunotherapy simultaneously does not result in chemioimmunotherapy, as the mechanisms of these therapeutic modalities may interact. Most chemotherapeutic agents (agents with no specific targets) are cytotoxic that can influence the majority of cell types in the human body's reproduction and growth in addition to killing cancer cells.⁹⁰ In conclusion, combining immunotherapy and chemotherapeutic agents can improve cancer therapy by increasing the antitumor response in the TME.

Cancer therapy has been immensely reformed through immune checkpoint blockade (ICB) immunotherapy, particularly antibodies against PD-1, CTLA-4, and PD-L1.⁹¹ However, ICB immunotherapy exhibits inadequate efficiency in most patients and may lead to substantial toxicity.⁹² Thus, more efficient, safer combinatorial therapeutic approaches including ICB are underway. PD-L1 is expressed over the tumor surface, and the antigen-presenting cells can interrelate with PD-1 expressed over the stimulated T cells, causing T-cell apoptosis, inactivation, and depletion.^{93,94} Thus, hindering the PD-1/PD-L1 pathway using anti-PD-1 and/or anti-PD-L1 antibodies has established potential therapeutic efficiency in various cancer



types, including melanoma.^{95–98} Furthermore, repetitive administration of anti-PD-1 antibodies can lead to severe immune-mediated adverse effects.^{99,100}

Additionally, tumor-associated macrophages (TAMs), a vital constituent of the tumor microenvironment, play a crucial role in tumor development and progression.¹⁰¹ TAMs are broadly categorized as M1 macrophages (M1-TAMs) and M2 macrophages (M2-TAMs). Foreign antigens and tumor cell eradication can be attained by M1-TAMs, which express higher levels of IL-12 and IL-23.¹⁰² The stability of M1-TAM and M2-TAMs has been related to angiogenesis, drug resistance, and immunosuppression within the tumor cells.¹⁰³ Additionally, CSF-1/CSF- and CCL2/CCR2-1R-targeting approaches often lead to monocyte and macrophage formation, increasing neo-angiogenesis and metastasis.¹⁰⁴

3.1.2. Chemo-photothermal therapy for cancer targeting.

The integration of multimodal treatment modalities in one system has demonstrated good therapeutic efficacy relative to single therapy. Chemo-photothermal combined therapy can maximize the synergistic effect, in which PTT accelerates the penetration and intracellular delivery of chemotherapeutic drugs into the tumour.^{105,106} Photothermal therapy is capable of exhibiting anticancer activity, but it usually needs direct contact with the source of light irradiation, which prevents its efficacy against distributed and metastatic tumors. Thus, it was observed that photothermal therapy combined with chemotherapy can activate potent anti-tumor resistance against distributed and metastatic tumors.¹³

Qing *et al.*¹⁰⁷ developed bortezomib (BZ), luteolin (LT) and indocyanine green (ICG) co-loaded pH-mediated supramolecular mPEG-based (BZ/LT-ICN@mPEG) hydrogels for the effective management of colorectal cancer through the combination of chemo-photothermal-photodynamic therapy.¹⁰⁷ In another study, Kong *et al.*¹⁰⁸ reported the anticancer potential of a fabricated injectable thermosensitive liposomal hydrogel system using a chemo (gemcitabine, a chemotherapeutic drug)-photothermal (DPP-BTz, a NIR-II photothermal agent) combined approach. The hydrogels significantly reduced the treated tumors by generating heat under the irradiation of a 1064 nm laser, breaching the liposomal layer and releasing the drug leading to death of tumor cells.¹⁰⁸ Costa *et al.*¹⁰⁹ developed polymeric (hyaluronic acid-conjugated with thiol groups/deacetylated chitosan grafted with maleimide groups) hydrogels for treating breast cancer through combined chemo-photothermal therapy. On the other hand, doxorubicin-loaded dopamine-condensed graphene oxide (DDGO) was synthesized for accomplishing NIR-responsive chemo-photothermal nanocarriers. Further, the polymeric hydrogel was simply mixed with DDGO to form a stable chemo-photothermal agent. These hybrid hydrogels significantly reduced the viability of breast cancer cells, showing improved combinatorial effects.¹⁰⁹

The combinatorial strategy has also assisted in overcoming the limitations of multi-drug resistance which is a complex cellular defensive mechanism of tumorous/carcinogenic cells to resist chemotherapeutic drugs leading to chemotherapy failure.¹¹⁰ In a study researchers reported the potential activity

of injectable hydrogels composed of doxorubicin (chemotherapeutic drug) conjugated with gold-manganese oxide nanoparticles which were further loaded with liposome-based self-assembled micelles against MDR hepatocellular carcinoma. The hydrogel significantly released the drug in a sustained manner under the presence of NIR laser irradiation (808 nm; 1 W cm⁻²; 10 min.) with enhanced antitumor efficiency against MDR HCC. Moreover, the *in vivo* results confirmed that the hydrogel system downregulated the *P*-glycoprotein, p53 and Bcl-2 level, while upregulated the Bax and caspase-3 level.¹¹⁰

3.1.3. Cationic polymer-mediated hydrogel systems for chemoimmunotherapy and chemophotothermal therapy. Traditional intravenous chemotherapeutic approaches have been reported with diverse limitations and systemic adverse effects such as hepatic or kidney dysfunction, myelosuppression, and neurotoxicity.¹¹¹ The injectable hydrogels can be significantly improved as per specific stimuli for specific cancer targeting including pH-sensitive, thermosensitive, photosensitive, and dual-sensitive hydrogels.¹¹¹ Alternatively, the injectable hydrogel-mediated systems help overcome the limitations of traditional intravenous chemotherapeutic approaches by releasing drugs/biomolecules to the targeted cancer or tumor site when conjugated with immunotherapy or radiotherapy or both, as described in Fig. 5.

Postsurgical treatment has exhibited significant importance for combating tumor reappearance and metastasis. Chen *et al.*¹¹² synthesized an *in situ* gel implant using pullulan and crosslinking chitosan for postsurgical care. They co-loaded cycloamine (Cyc) with aCD47 for gel chemoimmunotherapy. The gels showed sequential drug release kinetics, with nanotherapeutics killing residual tumor cells and releasing tumor antigens. To restore macrophage functionality and activate anti-tumor immune responses, ACD47 was released over time in a sustained manner. Further investigations on 4T1 mouse breast cancer models concluded that *in situ* chemoimmunotherapy was effective, effectively augmenting anti-tumor effects and establishing a long-term immune memory to combat tumor metastasis.¹¹² The combinatorial effect of chemotherapy and immunotherapy for treating tumour or cancer has been well-explored. Han *et al.*¹¹³ explored a unique chemoimmunotherapy technique for targeting cancer cells that uses hydrogels as a localized drug delivery system. Chemoimmunotherapeutic agents such as doxorubicin (DOX) and vaccinia virus vaccine expressing Sig/E7/LAMP-1 (Vac-Sig/E7/LAMP-1) were loaded into chitosan hydrogels (CH-DOX). Co-administration of vaccinia virus-based vaccine and CH-DOX resulted in a synergistic antitumor effect as the hydrogel inhibited tumor growth. Moreover, it also elevated the CD8(+) T lymphocytes that are tumor-specific, extending the antitumor effects up to 60 days compared to monotherapy alone. This led to the foundation to rationally explore chemoimmunotherapy's antitumor efficacy.¹¹³

Similarly, Seo *et al.*¹¹⁴ used a biodegradable hydrogel platform to simultaneously administer an immunoadjuvant and an anti-cancer medication to patients for chemoimmunotherapy. The effect of the chitosan hydrogel (CH), loaded with a cancer






Fig. 5 Illustration representing various processes involved in injectable hydrogel-mediated cancer therapy: (A) chemotherapeutic strategies conjugated with immunotherapy or radiotherapy or both. (B) Injectable hydrogel system composed of bioactive molecules (chemotherapeutic agents or immunotherapeutic agents or both). (C) Controlled- or sustained release behaviour of bioactive molecules from the hydrogel matrix. (D) Biomolecules targeting cancer or tumors with improved efficacy leading to oncolysis or cell death.

drug and GM-CSF, on TC-1 cervical tumor growth in mice was assessed. The TC-1 tumor growth was decreased post-administration of the hydrogel containing cancer drug (DOX, cisplatin, or cyclophosphamide (CTX)) and GM-CSF. While CTX was found to be a more potent anti-cancer agent, intra-tumoral treatment of CH, a cancer medication, in combination with GM-CSF elicited a significant immunological response in E7-specific CD8(+) T cells.¹¹⁴ Gu *et al.*¹¹⁵ developed a silk-chitosan composite scaffold encapsulating the drug DOX and JQ1 (a small chemical inhibitor of the protein BRD4 and its bromodomain) for localized delivery in the acidic TME. The DOX-JQ1@Gel contains a pH-degradable group, which triggers an antitumor immunity response. Antitumor immunity was associated with chemotherapy-induced antigen release and JQ1-mediated PD-L1 checkpoint blockade. Local DOX-JQ1@Gel injection is anticipated to reduce systemic side effects while increasing immunotherapy's objective response rate.¹¹⁵ Wang *et al.*¹¹⁶ created twin-like core-shell nanoparticles (TCNs) composed of sorafenib and IMD-0354 (a TAM repolarization drug) focused on tumor-targeted chemoimmunotherapy. The *in vivo* investigations in Hepa1-6 tumor-bearing mice and phenotype analysis revealed that TCNs had superior effects to sorafenib alone. The combination treatment revealed enhanced and synergistic anticancer effects and superior polarisation capacities towards M2-type TAMs.¹¹⁶

The effectiveness of the available therapy options for cancer treatment is currently limited. A novel chemo-immunotherapy system combining DOX, IL-2 (interleukin-2), and IFN- γ (interferon-gamma) offers promise for improved treatment outcomes. It was developed for the local treatment of melanoma xenografts. The system showed short-term bursts and long-term sustained releases, with the hydrogel degrading completely. Within 3 weeks, the chemo-immunotherapy system including DOX, IL-2, and IFN- γ demonstrated effectiveness without inducing inflammatory reactions. In B16F10 cells, the DOX/IL-2/IFN- γ co-loaded hydrogel increased cell apoptosis and

induced G2/S phase cell cycle arrest. On the other hand, in an *in vivo* nude mouse model, the combined method improved therapy against B16F10 melanoma xenografts while causing no systemic adverse effects. Overall, using polypeptide hydrogels for localized DOX/IL-2/IFN- γ co-delivery offers a promising approach for efficient melanoma therapy.¹¹⁷

Chen *et al.*¹¹⁸ developed a hydrogel for localized chemoimmunotherapy. A polypeptide hydrogel with thermo-gelling capabilities was produced, including anti-cytotoxic T-lymphocyte-associated protein 4 (aCTLA-4), immune checkpoint blockade antibodies (anti-programmed cell death protein 1, aPD-1) and DOX. *In vitro* results showed that the hydrogel displayed sustained release of DOX and IgG model antibodies for more than 12 days. The DOX/aCTLA-4/aPD-1 co-loaded hydrogel dramatically increased tumor suppression, boosted anticancer immune response, and extended the survival time in mice with B16F10 melanoma. Furthermore, after surgical site injection, the hydrogel-based chemo-immunotherapy method substantially prevented tumor recurrence, demonstrating its promise for anti-tumor therapy and prevention.¹¹⁸ Akbari *et al.*¹¹⁹ loaded macrophage colony-stimulating factor (GM-CSF) and paclitaxel (PTX) into a hyaluronic acid (HA) hydrogel for cancer therapy. Further, tocopheryl polyethylene glycol (TPGS) and pluronic F127 were used to prepare micelles which were later loaded with PTX. *In vitro* and *in vivo* immunological activities were also assessed. The optimized formulation was tested in a mouse model of subcutaneous melanoma using the B16 F10 cell line. The hydrogel exhibited prolonged PTX release when compared to GM-CSF. Moreover, in melanoma-affected mice, the optimized formulation exhibited a potent anti-tumor effect compared to GM-CSF and PTX alone, post intra-tumoral administration.¹¹⁹ A melittin-RADA32 hybrid peptide hydrogel encapsulating doxorubicin (DOX) was developed by Jin *et al.*¹²⁰ for treating melanoma. The synthesized hydrogel exhibited an interweaving nanofiber structure and excellent biocompatibility, offered controlled drug release properties, and enhanced



the killing efficiency of melanoma cells. A single-dose injection of the MRD hydrogel retarded primary melanoma tumor growth by over 95%, recruiting activated natural killer cells. In addition, the hydrogel therapy efficiently activated M2-like tumor-associated macrophages (TAMs), promoting the generation of cytotoxic T cells to attack the residual tumors. Furthermore, successive injections of the MRD hydrogel resulted in the eradication of 50% of primary tumors and the induction of a robust immunological memory response, protecting against tumor recurrence after eradication.¹²⁰

4. Chemotherapeutic applications of various natural cationic polymer-derived injectable hydrogels

A significant challenge in delivering therapeutic agents to cancer tissues is the dynamic and complex tumor microenvironment (TME), often resulting in the off-target delivery of associated drugs.¹²¹ Therefore, drug delivery systems should be able to deliver the therapeutic payload in a controlled and targeted manner. Conventional approaches mainly aim to reduce toxicity and associated adverse effects and improve hydrophilicity, circulation time, and control of the release profile. Targeted and localized delivery is a reliable solution.^{122,123} Although advanced drug delivery systems such as microspheres and nanocarriers are developed, these fail to provide the initial burst release, jeopardizing their efficiency.¹²⁴ Another challenge is passive targeting by the enhanced permeation and retention (EPR) effect, which mainly relies on the tumor vascular permeability. This often fails in clinical settings due to tumor heterogeneity, variable tumour cell density, and tissue barriers.^{125–127} In addition, some limitations of active targeting include high interstitial fluid pressure in tumors and rapid elimination of the therapeutic payload by reticuloendothelial systems.¹²⁸ Therefore, nanoformulations may be less efficient as carriers for anticancer drugs owing to their small size, which aids in their rapid elimination, and ability to interact non-specifically with normal cells, which results in low penetration into tumor sites.¹²⁹ According to Wilhelm *et al.*, among the applied nanoparticles, the fraction of nanoparticles that penetrate tumor cells is less than 0.7%.¹³⁰

Hydrogels are attractive delivery systems for localized and targeted therapy due to their sustained delivery. In addition, unlike active and passive targeting techniques, hydrogels work well regardless of tumor blood supply and microvasculature.^{27,28} Hydrogels have improved clinical applications by significantly improving RNAi delivery systems.^{129,131} Moreover, they can enhance the physical stability of the therapeutic drugs inhibiting drug precipitation.²⁹ Injectable hydrogels for cancer therapy are another hot topic that has demonstrated excellent properties of hydrogels;^{132,133} mechanisms and strategies of the same are illustrated in Fig. 6a and b.

Hydrogels are also capable of delivering multiple therapeutic payloads at once. Often due to the heterogenic nature of tumors and the presence of malignant cells at distinct stages of

growth and divisions, a single drug might not be efficient in inhibiting tumor growth.¹³⁴ Concurrent delivery of multiple medications can be a promising strategy in such cases.¹³⁵ This strategy further improves the treatment efficacy by lowering associated adverse effects. For instance, Hu *et al.* prepared a thermosensitive injectable hydrogel for the codelivery of lapatinib and paclitaxel, which upon peritumoral injection resulted in a synergistic effect.¹³⁶

Moreover, concurrent delivery of therapeutic agents with DNA or RNAi can yield promising results in overcoming angiogenesis and tumor resistance to drugs by inhibiting efflux pumps associated with multidrug resistance.¹³⁵ In a study by Strong *et al.*, concurrent delivery of doxorubicin and DNA enclosed within a poly(*N*-isopropyl acrylamide-*co*-acrylamide) hydrogel with near-infrared absorbing silica-gold nano-shells was achieved.¹³⁷ In another study by Guo *et al.*, an injectable linoleic acid-coupled pluronic hydrogel carrying paclitaxel and protein kinase B (AKT)-targeted gene therapy exhibited a synergistic anticancer effect by downregulating AKT signaling further inducing apoptosis.¹²¹

Furthermore, hydrogels can also be used for the codelivery of radioisotopes and chemotherapeutic agents for cancer therapy. For instance, Huang *et al.* developed a macroscale thermosensitive injectable micellar hydrogel for the co-delivery of iodine-131 labeled hyaluronic acid (¹³¹I-HA) and doxorubicin for enhanced *in situ* synergistic chemoradiotherapy.¹³⁸ The therapeutic application of multiple drugs for synergistic effects often requires separate encapsulation of the therapeutic payload. Wang *et al.* developed PEGylated hydrocarbon nanoparticles with PEGylated fluoro-carbon nanoparticles for encapsulating doxorubicin and paclitaxel into different hydrogel compartments.¹³⁴ Another proposed approach for controlled cargo release from the hydrogel is incorporating nanoparticles. In a study, a gold nanoparticle enclosed within a dextran-based implantable dendrimer hydrogel was reported for the co-delivery of cisplatin and miRNAs.¹³⁹ Many engineered injectable hydrogels prepared from cationic polymers of natural origin are briefly discussed in this section.

4.1. Chitosan-based injectable hydrogels for targeted chemotherapy

Chitosan, a natural polymer discovered in 1859 by C. Roget, is the second most abundant polysaccharide after cellulose. It is usually obtained by alkaline deacetylation of chitin mounds, mostly in crustacean shells. Structurally chitosan is like glycosaminoglycan, consisting of β -(1–4) linked D-glucosamine and N-acetyl-D-glucosamine units arranged randomly.^{140,141} Chitosan has high biocompatibility, low immunogenicity, and better intrinsic bacteriostatic activity and thus is widely used for various biomedical applications.^{138,142} In another study,¹⁴³ researchers developed thermo- and pH-responsive hydrogels by conjugating poly(*N*-isopropylacrylamide-*co*-itaconic acid) and chitosan *via* ionic crosslinking using glycerophosphate for effective delivery of doxorubicin against breast cancer. Recent advancements in chitosan-based injectable hydrogels are discussed hereafter.





Fig. 6 (a) Schematic representation of an injectable *in situ* forming hydrogel for intratumoral injection. (b) Schematic illustration of intratumoral injection of anticancer drug-loaded injectable hydrogels. Reproduced from ref. 133 with permission from MDPI, copyright 2021.

A chitosan-based thermo-responsive hydrogel was prepared by Ahsan *et al.* for efficient and sustained delivery of disulfiram (CS-DS) (Fig. 7a). The drug was firmly distributed in the injectable thermo-responsive hydrogels, confirmed by SEM micrographs (Fig. 7b). The cumulative drug release profile showed a better release of DS from injectable hydrogels (Fig. 7c). Moreover, CS-DS injectable hydrogels exhibited better cellular uptake in the treated SMMC-7721 cell line (Fig. 7d), ensuing significant anticancer activity against hepatocellular carcinoma.¹⁴⁴ Similarly, dialdehyde-functionalized polyethylene glycol (DF-PEG) and β -glycerophosphate (GP) cross-linked chitosan (CS) hydrogels were prepared by Han *et al.* for sustained delivery of doxorubicin hydrochloride (DOX) for antitumor therapy *via* intratumoral injection. In Heps tumor-bearing mice, the resultant hydrogel exhibited a superior tumor

inhibition rate.¹⁴⁵ Moreover, for localized delivery of an anti-cancer drug, 5-fluorouracil, for breast cancer treatment, Abdelatif *et al.* prepared a chitosan hydrogel and investigated its efficacy in the MCF-7 cell line both *in vitro* and *in vivo*. Reduction in tumor volume and tumor marker levels in blood showed that injectable hydrogels are potential drug delivery systems for anticancer drugs.¹⁴⁶

Wu *et al.* constructed a crosslinked chemical and physical composite injectable gel for co-delivery of doxorubicin, recombinant human interferon-gamma (IFN- γ), and the protein cytokine recombinant human interleukin-2 (IL-2).¹⁴⁷ When administered to the xenograft tumor-bearing mice, this exhibited a synergistic anticancer effect by downregulating Janus kinase/signal transducer and activating JAK/STAT pathways. Further, a pH-responsive self-healing injectable hydrogel based





Fig. 7 (a) Schematic illustration of the steps involved in the formulation of thermo-responsive CS-DS injectable hydrogels. (b) SEM micrographs of thermo-responsive CS-DS injectable hydrogels at various magnifications and cross sections. (c) Cumulative release (%) of DS from thermo-responsive CS-DS injectable hydrogels over time at varying pH ($n = 3$). (d) Cell uptake of free DS and FITC-tagged CS-DS injectable hydrogels in the hepatocellular carcinoma SMMC-7721 cell line after 4 h incubation; scale bar: 20 μm . Reproduced from ref. 144 with permission from American Chemical Society, copyright 2020.

on *N*-carboxyethyl chitosan was prepared by Qu *et al.* for hepatocellular carcinoma therapy.²¹ Wang *et al.* prepared an injectable chitosan-based hydrogel for antitumor and antimetastatic effects on hepatocarcinoma using Bel-7402 cells.¹⁴⁸ Belali *et al.* prepared a cell-specific and pH-sensitive nanostructured chitosan hydrogel as a potential photosensitizer carrier for selective photodynamic therapy.¹⁴⁹ To improve intraperitoneal chemotherapy in colon carcinoma, Chen *et al.* constructed a thermosensitive poly(*N*-isopropyl acrylamide)-based hydrogel (HACPN) loaded with doxorubicin and investigated its effects on CT-26 cells *in vitro*.¹⁵⁰

4.2. Cyclodextrin-based injectable hydrogels for targeted chemotherapy

Injectable hydrogels can be employed for dual loading of both hydrophilic and hydrophobic drugs, as their primary (6-OH) and secondary surfaces (2-OH, 3-OH) are formed by hydroxy hydrophilic medicines whereas ether along with carbon-hydrogen accounts for the hydrophobic cavities.¹⁵¹ Due to their good solubility and permeability, along with specific recognition and bonding abilities with numerous inorganic, organic, and

biological substrates and polymer chains,^{152–154} cyclodextrins can be efficiently used as a carrier for drug delivery applications.

Kuang *et al.* synthesized A-PEG-A and -PEG-T (Fig. 8a), and further conjugated with α -cyclodextrin (α -CD) for developing injectable hydrogels (Fig. 8b and c) for sustained release of antitumor drugs. Initially, the *in vivo* development of the G2 hydrogel was performed (Fig. 8d). Later on, *in vivo*, experiments employing U14 cancer cell xenograft-bearing mice (Fig. 8e) showed that the intratumoral injection of a DOX-loaded A-PEG-A/T-PEG-T/ α -CD gel inhibited tumor growth more effectively than that of free DOX.¹⁵⁵ In another study, Fiorica *et al.* investigated the penetration (in solid tumors) and release profile of anticancer drug DOX, embedded in hyaluronic-((2-aminoethyl)-carbamate) acid (HA-EDA) conjugated with sulfone functionalized β -cyclodextrins (HA-EDA/ β -CD-VS(DOX)). The complex hydrogels significantly inhibited the growth of colorectal carcinoma micro-masses cultured under 3D conditions. *In vivo*, studies have validated that tumor mass was reduced considerably without inducing any localized or systematic side effects.¹⁵⁶ Similarly, Fu *et al.* prepared a paclitaxel-loaded

injectable micellar supramolecular hydrogel composed of α -cyclodextrin (α -CD) and monomethoxy poly(ethylene glycol)-*b*-poly(caprolactone). This resulted in enhanced biological activity of paclitaxel over free drug. In addition, it was shown that by altering the composition of α -CD in the hydrogel, the release profile of the drug could be modified.¹⁵⁷

4.3. Cellulose-based injectable hydrogels for targeted chemotherapy

Cellulose, one of the most frequently found polymers in nature, consists of anhydrous-D-glucopyranose units linked by 1,4 linkages.¹⁵⁸ Its unique physicochemical properties and wide applications have invoked a greater interest among researchers. Biocompatibility, cost-efficiency, and high thermal and mechanical stability are among the numerous factors that promote its use for broad biomedical applications. Cellulose is insoluble in water and most organic solvents due to strong bonds and intermolecular hydrogen bonding between chains; as a result, chemical modifications are done.¹⁵⁹ Examples of modified cellulose include ethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, oxidized cellulose, carboxymethyl cellulose, cellulose acetate, and cellulose triacetate, the common derivatives of cellulose obtained through chemical modification processes such as etherification, esterification, and oxidation.¹⁶⁰ Cellulose hydrogels are predominantly used in drug delivery applications owing to their highly porous structure and mechanical properties. A biodegradable, multicompartmental, thermo-responsive hydrogel of cellulose and N-isopropyl acrylamide was prepared for dual loading of doxorubicin and niclosamide by Andrade *et al.* The drug release profile of both drugs was retarded (only 4% of doxorubicin and 30% of niclosamide were released after 1 week) due to the presence of cellulose, promoting cell death in cell lines HCT116 and OVCAR-3.¹⁶¹

You *et al.* prepared a quaternized cellulose (QC) and cationic cellulose nanocrystals (CCNs) crosslinked with β -glycerophosphate (β -GP) (Fig. 9a) with rigid rod-like (Fig. 9b) structure for localized and sustained drug delivery of doxorubicin (DOX). The administration of the hydrogel showed a specific site location (Fig. 9c(i)–(iii)), with significant results confirmed through histological images observed at varying time intervals (0–16 days) (Fig. 9c(iv)–(ix)). The administration of the DOX-loaded optimized hydrogel significantly suppressed the progression of cancer cells and also the rate of survival augmented vividly (Fig. 9d), signifying an enhanced chemotherapeutic efficacy due to the sustained release of DOX.¹⁶² In another study, a thermo-reversible hydrogel of methyl cellulose was prepared for the controlled release of docetaxel. The formulation exhibited sustained drug release over 25 days, lowering tumor growth and promoting survival in B16F10 melanoma-induced mouse models.¹⁶³ Weng *et al.* prepared an *in situ* forming carboxymethyl cellulose hydrogel for sustained doxorubicin delivery, which exhibited a mere 30% release over 78 hours.¹⁶⁴ Ding *et al.* prepared a hydroxypropyl methylcellulose injectable hydrogel for the co-delivery of paclitaxel and temozolomide for glioma treatment.¹⁶⁵ An alginate

and sodium carboxymethyl cellulose hydrogel for dual drug delivery of aspirin and methotrexate was developed by Sheng *et al.* for colorectal cancer treatment.¹⁶⁶ Balahura *et al.* designed 5-fluorouracil-loaded cellulose nanofiber hydrogels for promoting pyroptosis activation in breast cancer cells.¹⁶⁷ Bollareddy *et al.* prepared a transferosome hydrogel containing a 5-fluorouracil and etodolac combination for synergistic oral cancer treatment.¹⁶⁸ A self-healing cellulose injectable hydrogel for sustained cancer therapy was developed by Jiang *et al.*¹⁶⁹ In addition, Capanema *et al.* acquired doxorubicin-loaded bioengineered carboxymethyl cellulose hydrogels for topical chemotherapy of melanoma skin cancer.¹⁷⁰

4.4. Dextran-based injectable hydrogels for targeted chemotherapy

Dextran is a natural polymer that owing to its high availability, low cost, and ability to undergo easy chemical modifications is used widely for wide biomedical applications. It consists of glucose monomers linked by α -1,6 glycosidic bonds. Dextran has invoked greater interest as a drug delivery carrier due to its high stability, absence of toxicity, hydrophilicity, and biodegradability,¹⁷¹ and it enables enhanced penetration of chemotherapeutic agents in tumor masses.¹⁷² This has allowed the fabrication of effective delivery vehicles for cancer treatment.¹⁷³ Chemical modifications such as oxidation,^{80,174} conjugation to thiol,¹⁷⁵ and acrylic¹²⁹ group of dextran yielded effective carriers for the delivery of genes¹²⁹ and cytotoxic drugs.^{80,174}

Liu *et al.* developed a sericin (isolated from *Bombyx mori*)/dextran (SC/DX)-based hydrogel (Fig. 10a and b) encapsulated with DOX for real-time *in vivo* monitoring and delivery of the therapeutic payload for malignant melanoma treatment (Fig. 10c). The hydrogel exhibited superior gelation time, biodegradability, and biocompatibility with improved drug loading and controlled release of both small-molecular and macro-molecular drug entities with better storage abilities (Fig. 10d–f). In addition, drug distribution was confirmed through morphological studies using SEM (Fig. 10g). Furthermore, the *in vivo* results showed that SC/DX-loaded DOX hydrogels exhibited superior anticancer effects by significantly reducing the tumour size and improving the survival rate of treated B16-F10-induced mice (Fig. 10h–m).⁸⁰

Luo *et al.* constructed an injectable hydrogel to act as a depot system for increasing drug concentration at the tumor site.¹⁷⁶ The nanocomposite hydrogel consisting of oxaliplatin (OXA)-conjugated G5 polyamidoamine (G5-OXA) and oxidized dextran (Dex-CHO) exhibited increased drug retention and tumor penetration *via* active transcytosis. *In vivo* studies performed on the 4T1 tumor model revealed inhibited primary tumor growth and metastasis.¹⁷⁶ Similarly, dextran methacrylate hydrogel microneedles loaded with doxorubicin and trametinib for continuous transdermal administration of melanoma were prepared by Huang *et al.*¹⁷⁷ Further, van Es *et al.* prepared a dextran hydrogel and holmium-poly(L-lactic acid) microspheres and investigated them by radionuclide and histological pilot study through tumor embolization in a Vx2






Fig. 8 (a) Scheme for the synthesis of adenine-terminated poly(ethylene glycol) (A-PEG-A) and thymine-terminated poly(ethylene glycol) (T-PEG-T). (b) Images of an A-PEG-A/T-PEG-T/ α -CD aqueous solution and G2 (B-PEG10k-B: 10% w/w) sample injectable hydrogel. (c) The mechanism associated with the gelation of the supramolecular hydrogel. (d) Photographs of (i) *in vivo* development of the G2 hydrogel within subcutaneous tissue post-treatment of 30 min (marked with red dots); (ii) G2 hydrogel-separated skin of a treated animal (rat); (iii) the equivalent SEM images of the hydrogel. (e) Graphs highlighting the alterations in (i) relative tumor volume and (ii) relative body weight of varying samples that were injected intratumorally into the xenograft-bearing mice (U14) after showing an initial tumor volume of 150–250 mm³. Reproduced from ref. 155 with permission from Royal Society of Chemistry, copyright 2014.

rabbit head and neck cancer model.¹⁷⁸ Solomevich *et al.* designed biodegradable pH-sensitive dextran phosphate hydrogels loaded with prospidine (DP-PrH) for local tumor therapy. The hydrogels inhibited the propagation of Hep-2 and HeLa cells in a dose-dependent manner. In addition, the hydrogels demonstrated superior antitumor effects than pure drugs.¹⁷⁹ Saboktakin *et al.* encapsulated 5,10,15,20-tetrakis (meso-hydroxyphenyl)porphyrin (mTHPP), a porphyrin-based PS agent, into hydrogels for photodynamic treatment of cancer.¹⁸⁰

4.5. Gelatin-based injectable hydrogels for targeted chemotherapy

Gelatin is a naturally occurring biodegradable polymer obtained from acid/alkali hydrolysis of collagen. It is non-toxic, non-irritant,

consists of denatured proteins, and has been widely used in pharmaceutical and biomedical industries due to its biodegradability.^{181–184} It comprises 18 different amino acids, arranged randomly with ample free carboxyl and amino groups that pave the way for electrostatic interactions. Further, increased free carboxyl and amino groups in alkali and acid-treated gelatin make it a suitable carrier for the controlled release of drugs and peptides.¹⁸⁵

Laser-triggered injectable gelatin hydrogels were prepared by Li *et al.*, for combinatorial up-conversion of fluorescence imaging and antitumor chemo-photothermal therapy.¹⁸⁷ Ding *et al.* prepared a gelatin hydrogel containing cisplatin loaded with gelatin (CDPP)/poly(acrylic acid) nanoparticles (Fig. 11a and b). It was observed that due to body temperature, the CDDP-NP-Jelly (CNJ) coating over the tumour progressively






Fig. 9 (a) Schematic illustration of hydrogel synthesis using hydrogel precursors and injectable QC/CCN/ β -GP nanocomposite hydrogels. (b) TEM images of (i) CN and (ii) CCN. (c) Comprehensive view: (i) before and (ii) after s.c injection of the hydrogel (optimized), and (iii) subsequent segmentation after 10 min of post-injection. Histological micrographs of s.c implantation of the optimized hydrogel treated within nude mice at (iv) 0, (v) 2, (vi) 4, (vii) 8, (viii) 12, and (ix) 16 days. The hydrogels are situated on the left side of the blue lines. (d) The illustrative images of (i) the tumors after various treatments, (ii) the tumor volume, and (iii) the rate of survival of each treated group. (iv) Histological micrographs of the H&E stained sections of different organs of treated mice after various treatments at 8 days. Reproduced from ref. 162 with permission from American Chemical Society, copyright 2011.

converted into a gelatinous sol *in vivo* (Fig. 11c). Results of *in vitro* cytotoxicity studies for 48 h showed significant findings for free CDDP, CNPs, and CNJ against treated adenocarcinoma (MKN-28) cells and mouse hepatoma (H22) cells (Fig. 11d–f). Further, significant *in vivo* findings were noticed for the samples isolated from the treated mouse model using typical fluorescence microscopy (Fig. 11g), dark-field microscopy images (Fig. 11h), and immunohistochemical assay (Fig. 11i). The implantation of the jellies comprising CDDP-loaded nanoparticles over the tumor tissue hindered tumor growth. It extended the lifetime of the treated animals (mice) compared to animals treated with i.v. injection of CDDP-loaded nanoparticles in a murine hepatoma H22 cancer model.¹⁸⁶ In another study, Yamashita *et al.* reported the effectiveness of

cisplatin-loaded gelatin hydrogels and anti-tumor activity in the peritoneal metastasis murine model of the human gastric cancer MKN45-Luc cell line.¹⁸⁸ The formulation further prolonged the survival time ($p = 0.0012$) and suppressed the *in vivo* tumor growth ($p = 0.02$), additionally releasing cisplatin in a controlled manner (30% drug remaining in the murine abdominal cavity after 7 days). An interleukin-12 (IL-12) loaded gelatin hydrogel was prepared by Liu *et al.*, and was investigated for sustained release of IL-12 in transplanted colon carcinoma C57BC/6 N mice.¹⁸⁹

Studies have also reported a few other cationic polymeric hydrogel-based systems for effectively delivering chemotherapeutic agents. In a study, hyaluronic acid (HA), a non-sulfated glycosaminoglycan, predominantly found in joints



biocompatibility and hydrophobicity is widely used in the biomedical field. Moreover, its hydroxyl and carboxyl groups can be chemically altered to achieve the desired properties.¹⁹⁸ Cisplatin dendrimers to breast and lung cancer cells were delivered efficiently through an injectable hydrogel prepared *via* ionic gelation.¹⁹⁹ Moreover, incorporating moieties such as N-isopropyl acrylamide led to the formation of thermo-responsive hydrogels to deliver




Fig. 11 (a) Schematic representation of the synthesis of CDDP-loaded gelatin-poly(acrylic acid) nanoparticles (CNPs). (b) Schematic representation of CDDP-NP-Jelly (CNJ) coating over the tumor, which progressively converts into a gelatinous sol *in vivo*, because of body temperature. *In vitro* cytotoxicity (48 h) of (c) free CDDP and CNPs against adenocarcinoma (MKN-28) cells (48 h); (d) free CDDP and CNPs against mouse hepatoma (H22) cells; (e) free CDDP and CNJ against MKN-28 cells. (f) LSCM image of MKN-28 cells incubated with CNPs, labeled by RBITC (37 °C, 2 h). (g) Typical fluorescence microscopy micrographs of tumor slices isolated from mentioned FITC-sample-treated mouse models. (h) Illustrative dark-field microscopy image of tumor slices isolated from sample-treated mice. Dark-field microscopy image overlapped with vasculature fluorescence, displaying the spreading of the groups of GEL-PAAu hybrid NPs (bright spots) related to the blood vessels (red) in the internal portions of the tumor. The arrows indicate the site of bright spots. (i) Characteristic photos of immunohistochemical samples comprising sliced caspase-3 (green) and PECAM-1 (red) in diverse groups specified. Reproduced from ref. 186 with permission from American Chemical Society, copyright 2011.

doxorubicin micelles²⁰⁰ and genes²⁰¹ for osteosarcoma and prostate cancer.

4.6. Polypeptide-based injectable hydrogels for targeted chemotherapy

Traditional chemotherapeutic drugs have significant drawbacks. Tumors, for example, can develop resistance to treatment, higher relapse chances post-treatment, and secondary malignancies due to drugs used against metastatic cancer.²⁰²

Drugs that may specifically eliminate cancer cells are still in high demand, effectively treating slow-growing and dormant cells while avoiding chemoresistance mechanisms. A steadily increasing amount of research suggests that peptides may help discover and develop cancer drugs.²⁰² Peptides are ideal candidates for cancer treatment due to their excellent tissue penetrability, low immunogenicity, and low manufacturing costs, and modification is simple for enhancing *in vivo* stability and biological activity.²⁰² Due to secondary conformations that are



unique, variable functions, and, most significantly, stimuli-enhanced therapeutic efficacy and minimizing adverse effects, stimuli-responsive polypeptide nano-assemblies have great potential for cancer nanomedicines.²⁰³ Owing to the above advantages, various endogenous stimuli (*e.g.*, pH, reduction, reactive oxygen species, adenosine triphosphate, enzymes, *etc.*) and exogenous light stimuli (*e.g.*, UV and near-infrared light) that are biologically relevant are used to create stimulus-responsive polypeptide nanoassemblies which are currently widely used.²⁰³

Peptide-based and peptide-conjugated delivery systems often comprise peptides produced from viral protein molecules that help viruses transfer their genome into host cells and have a high delivery efficiency.²⁰⁴ Targeting tumor microenvironments (TME) and improving aspects such as cellular absorption and lysosomal degradation pathways were also inhibited, and controlled and sustained therapeutic release were provided through peptide-based systems.²⁰⁵ Peptides, irrespective of their origin, possess specific biochemical properties, based on which they are classified as cell-penetrating, fusogenic, and targeting peptides. These all classes of peptides are widely used as therapeutic modalities (peptide vaccines), and as drug carriers for cancer therapy.²⁰⁶ Furthermore, PGMATRIX, a peptide hydrogel 3D scaffolding technology for cell culture, has recently been reported to grow organoid-like spheroids physiologically mimicking the 3D microenvironment that can be used as an *in vitro* 3D model for investigating cell activities, which is expected to improve the prediction rate.²⁰⁷

To successfully block the Arginase 1 (ARG1) pathway, Ren *et al.*²⁰⁸ synthesized an injectable hydrogel loaded with an L-norvaline-based immunomodulating gelator. The gelator, a diblock copolymer, consists of an L-norvaline-based polypeptide block, which ensures high drug loading of L-norvaline and controlled release in tumor microenvironments *via* responsive peptide bond cleavage. The hydrogel and DOX were effective immunotherapies for primary tumor removal, abscopal tumor suppression, and pulmonary metastasis inhibition. This novel approach offers a strong injectable hydrogel technology that effectively reverses ARG1 immunosuppressive conditions, resulting in enhanced immunotherapy.²⁰⁸ Jin *et al.*²⁰⁹ synthesized an injectable hydrogel using genetically engineered polypeptide and hollow gold nanoshells (HAuNS) for treating HepG2 tumors. The hydrogel was created by layering DOX and PC₁₀A, with DOX having a positive charge and PC₁₀A having a negative charge, further coating negatively charged HAuNS. The hybrid PC₁₀A/DOX/HAuNS nanogel was dissolved in polypeptide PC₁₀A to create the multifunctional hydrogel PC₁₀A/DOX/HAuNS. DOX was absorbed by the HAuNS and then incorporated in the PC₁₀A hydrogel, allowing sequential drug release for sustainable chemotherapy. Furthermore, tumor-bearing mouse experiments *in vitro* and *in vivo* revealed a significant improvement in tumor inhibition by the combination of chemo-photothermal therapy or chemotherapy alone.²⁰⁹

Garrett *et al.*²¹⁰ developed a diblock co-polypeptide hydrogel (DCH) to test injectable hydrogel-based carrier systems for

chemotherapeutics in glioblastoma treatment. The DCH could carry and release paclitaxel, a highly potent compound against primary gliomasphere cells. The DCH showed minimal tissue reactivity in the immune-competent mouse brain and was well tolerated. Moreover, Cremaphor-taxol or hydrogel caused less tissue damage, cellular inflammation, and reactive astrocytes. *In vivo* studies revealed that an injection of the paclitaxel-loaded hydrogel resulted in local tumor control and enhanced survival in the immunosuppressive mouse xenograft model of glioblastoma.²¹⁰ Liu *et al.*²¹¹ developed a supramolecular injectable hydrogel for local delivery of the DPPA-1 peptide and DOX. DOX can kill tumor cells and induce immunogenic cell death, while the DPPA-1 peptide blocks the PD-1/PD-L1 pathway, potentiating T-cell-mediated responses and minimizing side effects. This hydrogel's local injection demonstrated a synergistic cancer therapeutic effect, improving immunotherapy's objective response rate while minimizing systemic side effects.²¹¹

Song *et al.*²¹² used an injectable poly(L-valine) hydrogel as an antigen delivery vehicle and immunopotentiator for DC modulation in cancer immunotherapy. Further, *in vitro* and *in vivo* investigations revealed that the vaccine formulation of poly(I:C), TLR3 agonist, tumor cell lysates (TCL), and polypeptide hydrogel effectively recruits, activates, and matures DCs. Furthermore, melanoma-induced mice treated with subcutaneously injected hydrogel-based vaccine elicited a cytotoxic solid T-lymphocyte immune response. This demonstrates that the hydrogel vaccine stimulates the generation of CD8⁺ T cells in draining lymph nodes and tumor-infiltrating T-lymphocytes.²¹² The multifunctional polypeptide hydrogel has excellent potential as a green manufacturing and engineering material for cancer vaccines and anticancer applications. Hou *et al.*²¹³ developed a genetically engineered polypeptide hydrogel PC10ARGD for mammary carcinoma treatment. As a photosensitizer, the hydrogel contains a near-infrared silver sulfide (Ag₂S) QD and the water-soluble drugs DOX and Bestatin. The photothermal effect of the hydrogel resulted in continuous delivery of DOX, which can be used for *in situ* vaccination. *In vivo* tests revealed that laser irradiation of the Ag₂S QD/DOX/Bestatin@PC10ARGD hydrogel activated anti-tumor immune effects, inhibiting tumor growth and distal lung metastatic nodules. A safer lower-temperature treatment strategy with multiple laser irradiation demonstrated more effective tumor-killing performance and increased immune cell penetration into tumor tissue.²¹³

Jin *et al.*²¹⁴ developed an injectable multifunctional hydrogel based on modified coiled-coil polypeptide and Ag₂S quantum dots (QDs) for long-term chemo-photothermal treatment and PTX. The preparation of hydrogels was done by dissolution of oil-soluble Ag₂S-QDs and PTX in PC₁₀A hydrogels. The combination treatment effectively suppressed the development of SKOV3 ovarian cancer tumors. Real-time monitoring of *in vivo* degradation was achieved using near-infrared fluorescence and photoacoustic imaging. These results revealed that the developed multifunctional injectable hydrogel could be a potential theranostic platform for sustained cancer treatments.²¹⁴



Table 1 Studies (*in vitro* and *in vivo*) showing the anti-cancer effects of various chemotherapeutic drug-encapsulated natural cationic polymeric hydrogel systems

Composition			Cancer model		Major outcomes	Ref.
Hydrogel	Therapeutic agent	Type	<i>In vitro</i>	<i>In vivo</i>		
CS	TA-ZnPe	Breast	MDA-MB-231	—	The TA-ZnPe was directly released in a sustained manner for 8 days evading the circulation system in the tumour acidic environment.	218
CS/β-GP/HA	DOX	Cervix	HeLa	—	The hydrogel adhered to the tumor site promoting site specific release. Reinforced mechanical strength helped in reduction of initial burst release from the hydrogel.	219
CS/β-GP	Liposome	Ovarian	A 2780	—	A thermoresponsive hydrogel for localized therapy, activated by the external thermal stimuli which resulted in on-demand scheduled dosing of medicaments.	220
CS/β-GP/CNT	Methotrexate	Breast	MCF-7	—	The hydrogel enhanced the anti-tumour effects of methotrexate by releasing the drug in a controlled manner.	221
CS/β-GP	DOX	Liver	N1-S1	N1-S1	The C/GP/DOX/Re-188-TiN colloids significantly inhibited tumors when compared with the control group post treatment.	222
CS-DA/oxPLN	DOX	Colon	HCT116	—	The release profile of DOX was enhanced by hydrogels effectively killing colon tumor cells.	223
oxHA	Anti-2B11	Breast	MDA-MB-231	MDA-MB-231	The hydrogel system induced cell apoptosis, and further reduced the invasive ability of cells by reducing the mitochondrial membrane potential of MCF-7 and MDA-MB-231 cells.	224
HA	MSNs	Breast	SKBR3	—	The hydrogel nanocomposite was able to provide a microenvironment with rich anticancer drugs for a prolonged period.	225
HA-Tyr	Interferon-α	Liver	HAK-1B	HAK-1B	HA-Tyr hydrogels effectively inhibited tumor growth with lower cell density and proliferating cells, and with more apoptotic cells.	226
HA-αCD	DOX	Squamous carcinoma	SCC	—	The hydrogel nanocomposite was able to provide a microenvironment with rich anticancer drugs for a prolonged period.	227
HA-Gln/PEG-8-SH-Lys	—	Breast	MCF7	—	—	228
PF127/HA	DOX	Colorectal	—	CT26	Co-delivery enhanced the efficacy of tumor inhibition	196
oxALG-PEI	Cisplatin and paclitaxel	Breast	MDA-MB-231	—	Programmed cell death was promoted by significant accumulation of mitochondrial ROS upon treatment.	229
oxALG-PEI	Cisplatin and paclitaxel	Liver	HepG2	—	The premature release of drugs was prevented by the hydrogel which provided an additional diffusion barrier against Cis-DDP.	pro-230
QCL-CCNCs	DOX	Murine Liver	—	H22	The hydrogel acts as a depot system for anticancer therapy	162
CL	—	Murine melanoma	B16	—	The hydrogel exhibited excellent photothermal response and enhanced stability and flexibility by possessing strong cellulosic walls and 3D networks with irregular micrometer-sized pores.	231
ALG	Cisplatin	Breast	MFC7	—	The hydrogel/DEP is-mediated repeated photothermal therapy suppressed tumor growth efficiently.	199
oxDEX-SRC	HRP and DOX	Melanoma	—	B16F10	The hydrogel achieved efficient drug loading and released the encapsulated drugs in a controlled manner suppressing tumour growth.	80
oxDEX	Platinum	Breast	MDA-MB-231	MDA-MB-231	For repeated photothermal therapy, the hydrogel was able to remain in tumors for prolonged periods leading to complete tumor regression.	174
MADEX-SH/MAHA	DOX	Murine breast	4T1	4T1	The macroporous hydrogels aided in the sequential release of Bi NPs and DOX significantly exhibiting synergistic antitumor effects <i>in vitro</i> .	175
GG	Paclitaxel	Bladder	T24	—	The LP-Gel exhibited enhanced adhesion on the urothelium, and increased bladder wall penetration, along with appreciable cytotoxicity in rat and human bladder cancer cells.	232
GG	DOX	Murine breast	4T1	4T1	—	233
AGR	DOX	Breast	MDA-MB-231	—	The entrapment efficiency of DOX was enhanced by the addition of divalent metal ions in the complex further prolonging the DOX release profile.	234
HPMCL/PF127/ALG	Paclitaxel and temozolomide	Murine glioma	C6	—	The gel exhibited superior antitumor performance by inducing autophagy.	165

Table 1 (continued)

Composition		Cancer model				Major outcomes	Ref.
Hydrogel	Therapeutic	Type	<i>In vitro</i>	<i>In vivo</i>			
ALG-NIPAAm	Major components agent	Type	<i>In vitro</i>	<i>In vivo</i>			
DOX	Prostate	AT3B-1N	—		The hydrogels released the drug in sustained manner enhancing its cellular uptake in drug resistant AT3B-1N cells achieving better killing efficiency.	200	
PEG-PEGdA	Lung cancer	NCI-H460	A549		The AuP loaded formulation exhibited 60% tumour inhibition after 14 days.	235	
PVA	Ovarian cancer	A2780/CP70	A2780/CP70		The hydrogel containing low dose CisP (30 µg) is as effective as 150 µg of CisP administered intraperitoneally in inhibiting tumour growth.	236	
SBP	Melanoma	—	B16F1		The therapeutic evaluation over 10 days indicated that Dox-loaded hydrogels successfully suppressed the increase in tumor size.	237	
IL-12 and GM-CSF	Lung carcinoma	HEK293	C57BL/6		Prolonged immune response with co-delivery of IL-12 and GM-CSF.	238	

Abbreviations: CS: chitosan; TA-ZnPe: tetra-aldehyde functionalized zinc phthalocyanine; β-GP: β-glycerophosphate; HA: hyaluronic acid; CNT: carbon nanotubes; DA: dihydrocaffeic acid; oxPLN: oxidized pullulan; oxHA: oxidized HA; Tyr: tyramine; CD: cyclodextrin; Gln: glutamine substrate peptide; PEG-8-SH: 8-arm PEG; PEG: poly(ethylene glycol); Lys: lysine; others, PF127 (PEO/PPO balance 70/30); PEO: poly(ethylene oxide); PPO: poly(propylene oxide); oxALG: oxidized alginate; PEI: poly(ethylene imine); QCL: quaternized cellulose; CCNCs: cationic cellulose nanocrystals; CL: cellulose; ALG: alginate; oxDEX: oxidized dextran; SRC: sericin; DEX: dextran; MADEX: methacrylated DEX; MAHA: methacrylated HA; AGR: agarose; GG: gellan gum; HPMCL: hydroxypropyl methyl cellulose; NIPAAm: N-isopropyl acrylamide; Sn: Tin; MSNs: mesoporous silica nanoparticles; AuBNS: gold nanobipyrinamides; PLA: polylactide; PLGA: poly(lactide-co-glycolide); BPNs: black phosphorus nanosheets; PAMAM: polyamidoamine dendrimer; Bi NPs: bismuth nanoparticles; CuS NPs: copper sulphate nanoparticles; DEX: dextran; DEX-SH: dextran sulphate; MPEG: monomethoxy poly(ethylene glycol); DPPE: dipalmitoylphosphatidylethanolamine; HRP: horseradish peroxidase; DOX: doxorubicin; GT: gelatin; PEG-PEGdA: poly(ethylene glycol) (PEG)-diacrylate (PEGdA); AuP: gold(III) porphyrin; PVA: poly(vinyl alcohol); CisP: cisplatin; SBP: sugar beet pectin; GM-CSF: granulocyte-macrophage colony-stimulating factor; IL-12: interleukin-12.

Liu *et al.*²¹⁵ synthesized a thermosensitive supramolecular hydrogel consisting of iodine-131 (I131)-labeled injectable thermosensitive methoxy PEG-*b*-poly(tyrosine) (PETyr-I131) for brachytherapy. The PETyr-I131 radioactive source was immobilized at the injection site and monitored in real-time with single-photon emission computed tomography. The SmacN7 peptide coupled with cell membrane-permeable oligoarginine (SmacN7-R9) therapy had no negative effects. The combination improved radiosensitivity in cancer cells. Because of its proximity to the primary tumor or postoperative cavity site, the thermosensitive supramolecular hydrogel platform conformally immobilized radionuclides and delivered radiosensitizers, offering a high chance of producing synergistic therapy outcomes while minimizing radiation-related negative effects.²¹⁵

Shi *et al.*²¹⁶ synthesized an injectable, biocompatible polypeptide hydrogel to deliver along with DOX an immune checkpoint inhibitor antibody that targets programmed death-ligand 1 (aPD-L1). DOX significantly induced immunogenic tumor and promoted an antitumor immune response. Furthermore, the simultaneous release of aPD-L1 at the tumor site increased the tumour inhibitory effect by inhibiting the PD-1/PD-L1 pathway and restoring the cytotoxic T cell tumor-killing effect. The aPD-L1 and Dox co-loaded hydrogel treatment of the B16F10 melanoma model resulted in remarkable tumor progression inhibition and animal survival prolongation.²¹⁶ Jin *et al.*²¹⁷ developed a multifunctional PC₁₀A/DOX/MoS₂ hydrogel for chemotherapy, photothermal therapy, and photodynamic therapy of 4T1 tumors. The hydrogel was prepared using positively charged DOX and negatively charged PC₁₀A, and the 2D MoS₂ nanosheet was used as both photothermal and photodynamic agent. *In vivo* tumor-bearing mouse experiments showed that combining chemo-photothermal-photodynamic therapy significantly enhanced tumor inhibition compared to photothermal therapy, photodynamic therapy, or chemotherapy alone. The PC₁₀A/DOX/MoS₂ hydrogel inhibited primary 4T1 breast tumours as well as distal lung metastatic nodules by activating antitumor immune actions.²¹⁷ Further, some significant effects of various natural cationic polymeric hydrogel systems are summarized in Table 1.

5. Clinical and pre-clinical status of various natural cationic polymer-derived injectable hydrogels for targeted chemotherapy

Hydrogels have exhibited diversified applications in cancer therapy owing to their versatility and flexibility. While conventional hydrogels are not sensitive to environmental changes,^{239,240} smart hydrogels could be affected by pH, temperature, and photoelectricity^{225,241,242} resulting in temporal and spatial control over the releasing rate, thus improving the therapeutic index of commonly used chemotherapeutics.²⁴³ This section provides the various cationic polymer-based injectable hydrogels widely used in cancer therapy. Further, a list of



Table 2 Pre-clinical/clinical status of natural polymeric hydrogels in cancer therapy

Hydrogel characteristics			Pre-clinical/clinical studies			
Component(s)	Stimuli responsiveness	Drug	<i>In vitro</i>	<i>In vivo</i>	Major outcomes	Ref.
CS/GB	Thermosensitive	ICG	HCC	—	The hydrogel was feasible for drug delivery and fluorescence imaging.	244
PLGA	Thermosensitive	PTX	M234-p	Mammary tumour	The hydrogel exhibits a four fold increase in efficacy over existing marketed formulations.	245
CS/GB	Thermosensitive	DOX	H22 and SMMC7721	Hepatoma	The thermosensitive hydrogel delivered DOX to the tumour site efficiently and constantly.	246
Hyaluronic acid (HA) and PF127	Thermosensitive	DOX and DOC	CT26	Colorectal carcinoma	The hydrogel was efficient in co-delivery of DOX and DOC further decreasing associated side effects and improving cancer management.	196
CS and GP	pH-sensitive	DOX	MCF-7	Breast cancer	The hydrogel exhibited pH dependent drug release at pH 5.5	143
CS-DA and oxidized pullulan	pH-sensitive	DOX and Amoxicillin	HCT-116	Colon tumour	Ideal for management of mucosal localised tumour and infection	223
CS/HA/GP	pH-sensitive	DOX	HeLa	Cervical cancer	The hydrogel was successful in cervical cancer management.	219
PPM	Photosensitive	PPM	A549	Lung cancer	The hydrogel was ideal for management of mucosal localised tumour and infection	247
DPC	Photosensitive	DOX and DNA	CEM	Lymphocytic leukaemia	The photosensitive hydrogel crosslinked with DNA helped in controlled release of DOX.	248
HA	Photosensitive	MMP	MDA-MB-231	—	The HA hydrogel proved to be an ideal biomimetic cell culture model for breast cancer research.	249

Abbreviations: CS: chitosan; GB: glycerophosphate; ICG: indocyanine green; HCC: hepatocellular carcinoma; PLGA: polylactic-*co*-glycolic acid; PTX: paclitaxel; DOX: doxorubicin; PF127: pluronic F127; DOC: docetaxel; CS-DA: chitosan dihydrocaffeic acid; PPM: hyperbranched polyprodrug; DPC: DNA polyacrylamide conjugate; MMP: matrix metalloproteinase.

clinical trials (Table 2) related to various hydrogel formulations gives an idea about the current research being conducted in this area.

6. Conclusion and future perspectives

The peculiar characteristics of hydrogels make them efficient carriers for drug delivery. Elementary results of clinical studies suggest combining combinational therapies with the standard conventional therapies for cancer treatment. The mode of delivery used during combinational therapy can enhance treatment efficacy and influence disease progression due to prolonged drug release time.⁶ This review brings forward the various therapeutic applications of cationic polymer-mediated injectable hydrogels. Different preparative strategies for synthesizing cationic polymers with desired properties and transport mechanisms for effective and specific delivery were discussed. Certain limitations of various conventional cancer therapies, like immunosuppression, modulation of tumor microenvironment's expression of tumor antigens, *etc.*, are still being researched, leading to surpassing these limitations.¹⁴ Studies have shown that chemotherapy has demonstrated disruption of the various suppressive pathways and lymphodepletion post administration of chemotherapy.¹⁵

Furthermore, the development of biodegradable cationic polymers with reduced toxicity and massive growth in polymer science have led to numerous therapeutic applications. Continuous research in multi-disciplinary areas of cationic polymers has further elucidated their role in cellular processes and established a guide for different designs. The bottleneck for

designing cationic polymers lies in surpassing the subcellular barrier, endosomal escape, and nuclear translocation. However, non-degradability and toxicity hindered the success of cationic polymers traditionally. Surface and structure modifications and novel carriers have been developed over the past few years to overcome these drawbacks. Incorporating more biodegradable cationic polysaccharides and natural cationic polymers may be widely used. The use of injectable hydrogels for anticancer therapy is widely recognized among researchers, but to effectively replace conventional therapies, continuous innovations and developments in the field of polymer science and injectables concerning structural aspects and design strategies are required. To effectively translate injectable hydrogels into clinical reality, future research should explore and emphasize combination therapy, utilizing chemotherapy, immunotherapy, and radiotherapy, by selecting suitable polymers tested both *in vitro* and *in vivo*, evaluating their cellular and molecular mechanisms.

Author contributions

SSD, MKA and KKK: conceptualization of the work. SSD, DS, BVKR, HS, and MKA: data collection and drafting. SSD and DS: made illustrations. JR, SSD, MD and KKK: finalized and reviewed the manuscript.

Conflicts of interest

The authors declare no conflict of interest for this work.



Acknowledgements

This research received no external funding.

References

- 1 C. Mattiuzzi and G. Lippi, *J. Epidemiol. Global Health*, 2019, **9**, 217–222.
- 2 J. Ferlay, M. Colombet, I. Soerjomataram, D. M. Parkin, M. Pineros, A. Znaor and F. Bray, *Int. J. Cancer*, 2021, DOI: [10.1002/ijc.33588](https://doi.org/10.1002/ijc.33588).
- 3 S. S. Das, S. K. Singh, P. R. P. Verma, R. Gahtori, B. Z. Sibuh, K. K. Kesari, N. K. Jha, S. Dhanasekaran, V. K. Thakur, L. S. Wong, S. Djearmane and P. K. Gupta, *Biomed. Pharmacother.*, 2022, **154**, 113654.
- 4 H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, *CA Cancer J. Clin.*, 2021, **71**, 209–249.
- 5 V. S. Sivasankarapillai, A. M. Pillai, A. Rahdar, A. P. Sobha, S. S. Das, A. C. Mitropoulos, M. H. Mokarrar and G. Z. Kyzas, *Nanomaterials*, 2020, **10**, 852.
- 6 P. M. Arlen, R. A. Madan, J. W. Hodge, J. Schlom and J. L. Gulley, *Update Cancer Ther.*, 2007, **2**, 33–39.
- 7 N. K. Jha, S. Arfin, S. K. Jha, R. Kar, A. Dey, R. Gundamaraju, G. M. Ashraf, P. K. Gupta, S. Dhanasekaran, M. M. Abomughaid, S. S. Das, S. K. Singh, K. Dua, S. Roychoudhury, D. Kumar, J. Ruokolainen, S. Ojha and K. K. Kesari, *Semin. Cancer Biol.*, 2022, **86**, 1086–1104.
- 8 K. Nurgali, R. T. Jagoe and R. Abalo, *Front. Pharmacol.*, 2018, **9**, 245.
- 9 L. A. Diaz and L. C. Cantley, *Cancer Discovery*, 2023, **13**, 797–798.
- 10 D. Hanahan, *Cancer Discovery*, 2022, **12**, 31–46.
- 11 J. J. Marin, M. R. Romero, A. G. Blazquez, E. Herraez, E. Keck and O. Briz, *Anticancer Agents Med. Chem.*, 2009, **9**, 162–184.
- 12 Harshita, M. A. Barkat, S. S. Das, F. H. Pottou, S. Beg and Z. Rahman, *Curr. Pharm. Des.*, 2020, **26**, 1167–1180.
- 13 G. H. Nam, Y. Choi, G. B. Kim, S. Kim, S. A. Kim and I. S. Kim, *Adv. Mater.*, 2020, **32**, e2002440.
- 14 Y. Yan, A. B. Kumar, H. Finnes, S. N. Markovic, S. Park, R. S. Dronca and H. Dong, *Front. Immunol.*, 2018, **9**, 1739.
- 15 R. Ramakrishnan and D. I. Gabrilovich, *Cancer Immunol. Immunother.*, 2013, **62**, 405–410.
- 16 T. D. Johnson and K. L. Christman, *Expert Opin. Drug Delivery*, 2013, **10**, 59–72.
- 17 M. Dhanka, V. Pawar, D. S. Chauhan, N. K. Jain, R. S. Prabhuraj, C. Shetty, M. K. Kumawat, R. Prasad and R. Srivastava, *Colloids Surf., B*, 2021, **201**, 111597.
- 18 Z. Sun, C. Song, C. Wang, Y. Hu and J. Wu, *Mol. Pharm.*, 2020, **17**, 373–391.
- 19 S. S. Das, P. Bharadwaj, M. Bilal, M. Barani, A. Rahdar, P. Taboada, S. Bungau and G. Z. Kyzas, *Polymers*, 2020, **12**, 1397.
- 20 A. Sood, S. S. Das, A. Dev, D. Bhardwaj, A. Kumar, G. Agrawal and S. S. Han, *Eur. Polym. J.*, 2023, **196**, 112323.
- 21 J. Qu, X. Zhao, P. X. Ma and B. Guo, *Acta Biomater.*, 2017, **58**, 168–180.
- 22 V. S. Sivasankarapillai, S. S. Das, F. Sabir, M. A. Sundaramahalingam, J. C. Colmenares, S. Prasannakumar, M. Rajan, A. Rahdar and G. Z. Kyzas, *Mater. Today Chem.*, 2021, **19**, 100382.
- 23 M. Norouzi, B. Nazari and D. W. Miller, *Drug Discovery Today*, 2016, **21**, 1835–1849.
- 24 S. Alfei, A. Zorzoli, D. Marimpietri, A. M. Schito and E. Russo, *Pharmaceutics*, 2022, **14**, 2444.
- 25 D. J. Overstreet, D. Dutta, S. E. Stabenfeldt and B. L. Vernon, *J. Polym. Sci., Part B: Polym. Phys.*, 2012, **50**, 881–903.
- 26 A. P. Mathew, S. Uthaman, K. H. Cho, C. S. Cho and I. K. Park, *Int. J. Biol. Macromol.*, 2018, **110**, 17–29.
- 27 J. Conde, N. Oliva, Y. Zhang and N. Artzi, *Nat. Mater.*, 2016, **15**, 1128–1138.
- 28 N. Huebsch, C. J. Kearney, X. Zhao, J. Kim, C. A. Cezar, Z. Suo and D. J. Mooney, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 9762–9767.
- 29 Z. Lin, W. Gao, H. Hu, K. Ma, B. He, W. Dai, X. Wang, J. Wang, X. Zhang and Q. Zhang, *J. Controlled Release*, 2014, **174**, 161–170.
- 30 J. Zhao, L. Wang, H. Zhang, B. Liao and Y. Li, *Pharmaceutics*, 2022, **14**, 2028.
- 31 T. Thambi, Y. Li and D. S. Lee, *J. Controlled Release*, 2017, **267**, 57–66.
- 32 L. Yu and J. Ding, *Chem. Soc. Rev.*, 2008, **37**, 1473–1481.
- 33 P. Bertsch, M. Diba, D. J. Mooney and S. C. G. Leeuwenburgh, *Chem. Rev.*, 2023, **123**, 834–873.
- 34 J. M. Alonso, J. Andrade Del Olmo, R. Perez Gonzalez and V. Saez-Martinez, *Polymers*, 2021, **13**, 650.
- 35 J. Su, J. Li, J. Liang, K. Zhang and J. Li, *Life*, 2021, **11**, 1016.
- 36 L. Ye, Y. Zhang, Q. Wang, X. Zhou, B. Yang, F. Ji, D. Dong, L. Gao, Y. Cui and F. Yao, *ACS Appl. Mater. Interfaces*, 2016, **8**, 15710–15723.
- 37 X. Li, X. Peng, R. Li, Y. Zhang, Z. Liu, Y. Huang, S. Long and H. Li, *Macromol. Rapid Commun.*, 2020, **41**, e2000202.
- 38 A. Deng, Y. Yang, S. Du, X. Yang, S. Pang, X. Wang and S. Yang, *Mater. Sci. Eng., C*, 2021, **119**, 111555.
- 39 X. Chen, B. Tan, S. Wang, R. Tang, Z. Bao, G. Chen, S. Chen, W. Tang, Z. Wang, C. Long, W. W. Lu, D. Yang, L. Bian and S. Peng, *Biomaterials*, 2021, **274**, 120895.
- 40 M. Ozeki and Y. Tabata, *J. Biomater. Sci., Polym. Ed.*, 2005, **16**, 549–561.
- 41 W. Hu, Z. Wang, Y. Xiao, S. Zhang and J. Wang, *Biomater. Sci.*, 2019, **7**, 843–855.
- 42 M. D. Konieczynska and M. W. Grinstaff, *Acc. Chem. Res.*, 2017, **50**, 151–160.
- 43 C. Echaliier, L. Valot, J. Martinez, A. Mehdi and G. Subra, *Mater. Today Commun.*, 2019, **20**, 100536.
- 44 H. C. Kolb, M. G. Finn and K. B. Sharpless, *Angew. Chem., Int. Ed.*, 2001, **40**, 2004–2021.
- 45 C. M. Nimmo, S. C. Owen and M. S. Shoichet, *Biomacromolecules*, 2011, **12**, 824–830.
- 46 Y. Zhang, L. Tao, S. Li and Y. Wei, *Biomacromolecules*, 2011, **12**, 2894–2901.



- 47 G. N. Grover, J. Lam, T. H. Nguyen, T. Segura and H. D. Maynard, *Biomacromolecules*, 2012, **13**, 3013–3017.
- 48 B. D. Mather, K. Viswanathan, K. M. Miller and T. E. Long, *Prog. Polym. Sci.*, 2006, **31**, 487–531.
- 49 V. S. Raghuwanshi and G. Garnier, *Adv. Colloid Interface Sci.*, 2019, **274**, 102044.
- 50 S. H. Hsu, Y. L. Leu, J. W. Hu and J. Y. Fang, *Chem. Pharm. Bull.*, 2009, **57**, 453–458.
- 51 J. Skubiszewska-Zięba, S. Khalameida and V. Sydorchuk, *Colloids Surf., A*, 2016, **504**, 139–153.
- 52 J. Hurler, A. Engesland, B. Poorahmary Kermany and N. Škalko-Basnet, *J. Appl. Polym. Sci.*, 2012, **125**, 180–188.
- 53 J. M. Zuidema, C. J. Rivet, R. J. Gilbert and F. A. Morrison, *J. Biomed. Mater. Res., Part B*, 2014, **102**, 1063–1073.
- 54 H. Goodarzi, K. Jadidi, S. Pourmotabed, E. Sharifi and H. Aghamollaei, *Int. J. Biol. Macromol.*, 2019, **126**, 620–632.
- 55 L. W. Wong, P. Pasbakhsh, W. T. Cheng, C. B. S. Goh and J. B. L. Tan, *Appl. Clay Sci.*, 2023, **232**, 106812.
- 56 S. Kumar, M. Prasad and R. Rao, *Mater. Sci. Eng., C*, 2021, **119**, 111605.
- 57 C. Fiorica, G. Pitarresi, F. S. Palumbo, N. Mauro, S. Federico and G. Giammona, *Carbohydr. Polym.*, 2020, **236**, 116033.
- 58 S. K. Samal, M. Dash, S. Van Vlierberghe, D. L. Kaplan, E. Chiellini, C. van Blitterswijk, L. Moroni and P. Dubrue, *Chem. Soc. Rev.*, 2012, **41**, 7147–7194.
- 59 A. K. Bajpai, S. K. Shukla, S. Bhanu and S. Kankane, *Prog. Polym. Sci.*, 2008, **33**, 1088–1118.
- 60 S. Huang and X. Fu, *J. Controlled Release*, 2010, **142**, 149–159.
- 61 N. Q. I. M. Noor, R. S. Razali, N. K. Ismail, R. A. Ramli, U. H. M. Razali, A. R. Bahaiddin, N. Zaharudin, A. Rozzamri, J. Bakar and S. M. Shaarani, *Processes*, 2021, **9**, 2227.
- 62 S. S. Das, S. Kar, S. K. Singh, P. R. P. Verma, A. Hussain and S. Beg, *Chitosan in Drug Delivery*, 2022, pp. 23–53, DOI: [10.1016/b978-0-12-819336-5.00009-1](https://doi.org/10.1016/b978-0-12-819336-5.00009-1).
- 63 Z. Zhou, F. Jiang, T.-C. Lee and T. Yue, *J. Alloys Compd.*, 2013, **581**, 843–848.
- 64 N. P. Birch and J. D. Schiffman, *Langmuir*, 2014, **30**, 3441–3447.
- 65 Y. Dong, W. K. Ng, S. Shen, S. Kim and R. B. Tan, *Carbohydr. Polym.*, 2013, **94**, 940–945.
- 66 S. Y. Ong, J. Wu, S. M. Mochhala, M. H. Tan and J. Lu, *Biomaterials*, 2008, **29**, 4323–4332.
- 67 J. W. Lu, Y. Miao, C. X. Guo, Q. F. Ke, J. H. Yin, S. M. Zhou and Y. P. Guo, *ACS Appl. Bio Mater.*, 2018, **1**, 1468–1477.
- 68 A. J. Highton, T. Kojarunchitt, A. Girardin, S. Hook and R. A. Kemp, *Immunol. Cell Biol.*, 2015, **93**, 634–640.
- 69 W. F. Lai, A. L. Rogach and W. T. Wong, *Chem. Soc. Rev.*, 2017, **46**, 6379–6419.
- 70 B. L. Peng, N. Dhar, H. L. Liu and K. C. Tam, *Can. J. Chem. Eng.*, 2011, **89**, 1191–1206.
- 71 N. Duran, A. P. Lemes and A. B. Seabra, *Recent Pat. Nanotechnol.*, 2012, **6**, 16–28.
- 72 S. M. Carvalho, A. A. P. Mansur, N. S. V. Capanema, I. C. Carvalho, P. Chagas, L. C. A. de Oliveira and H. S. Mansur, *J. Mol. Liq.*, 2018, **266**, 425–440.
- 73 C. Y. Li, W. Yuan, H. Jiang, J. S. Li, F. J. Xu, W. T. Yang and J. Ma, *Bioconjugate Chem.*, 2011, **22**, 1842–1851.
- 74 Y. W. Won, S. M. Yoon, C. H. Sonn, K. M. Lee and Y. H. Kim, *ACS Nano*, 2011, **5**, 3839–3848.
- 75 G. K. Zorzi, L. Contreras-Ruiz, J. E. Parraga, A. Lopez-Garcia, R. R. Bello, Y. Diebold, B. Seijo and A. Sanchez, *Mol. Pharm.*, 2011, **8**, 1783–1788.
- 76 J. Choubey and A. K. Bajpai, *J. Mater. Sci.: Mater. Med.*, 2010, **21**, 1573–1586.
- 77 S. Patra, P. Basak and D. N. Tibarewala, *Mater. Sci. Eng., C*, 2016, **59**, 310–318.
- 78 C. Park, C. L. Vo, T. Kang, E. Oh and B. J. Lee, *Eur. J. Pharm. Biopharm.*, 2015, **89**, 365–373.
- 79 M. Alibolandi, M. Mohammadi, S. M. Taghdisi, M. Ramezani and K. Abnous, *Carbohydr. Polym.*, 2017, **155**, 218–229.
- 80 J. Liu, C. Qi, K. Tao, J. Zhang, J. Zhang, L. Xu, X. Jiang, Y. Zhang, L. Huang, Q. Li, H. Xie, J. Gao, X. Shuai, G. Wang, Z. Wang and L. Wang, *ACS Appl. Mater. Interfaces*, 2016, **8**, 6411–6422.
- 81 H. A. Barkat, S. S. Das, M. A. Barkat, S. Beg and H. A. Hadi, *Future Oncol.*, 2020, **16**, 2959–2979.
- 82 P. Bharadwaj, S. S. Das, S. Beg and M. Rahman, in *Nanoformulation Strategies for Cancer Treatment*, ed. S. Beg, M. Rahman, H. Choudhry, E. B. Souto and F. J. Ahmad, Elsevier, Amsterdam, Netherlands, 2021, ch. 16, pp. 277–289, DOI: [10.1016/b978-0-12-821095-6.00020-3](https://doi.org/10.1016/b978-0-12-821095-6.00020-3).
- 83 H. A. Barkat, M. A. Barkat, M. Taleuzzaman, S. S. Das, M. Rizwanullah and H. A. Hadi, *Handbook of Research on Advancements in Cancer Therapeutics*, 2021, ch. 11, pp. 339–355, DOI: [10.4018/978-1-7998-6530-8.ch011](https://doi.org/10.4018/978-1-7998-6530-8.ch011).
- 84 P. Chytil, T. Etrych, C. Konak, M. Sirova, T. Mrkvan, B. Rihova and K. Ulbrich, *J. Controlled Release*, 2006, **115**, 26–36.
- 85 A. Mitra, T. Coleman, M. Borgman, A. Nan, H. Ghandehari and B. R. Line, *J. Controlled Release*, 2006, **114**, 175–183.
- 86 T. Wang, Y. Suita, S. Miriyala, J. Dean, N. Tapinos and J. Shen, *Pharmaceutics*, 2021, **13**, 520.
- 87 D. S. Chen and I. Mellman, *Immunity*, 2013, **39**, 1–10.
- 88 S. Liu, J. Li, L. Gu, K. Wu and H. Xing, *Int. J. Nanomed.*, 2022, **17**, 5209–5227.
- 89 Q. Jin, Z. Liu and Q. Chen, *J. Controlled Release*, 2021, **329**, 882–893.
- 90 V. Schirrmacher, *Int. J. Oncol.*, 2019, **54**, 407–419.
- 91 P. Sharma and J. P. Allison, *Science*, 2015, **348**, 56–61.
- 92 R. Kuai, W. Yuan, S. Son, J. Nam, Y. Xu, Y. Fan, A. Schwendeman and J. J. Moon, *Sci. Adv.*, 2018, **4**, eaao1736.
- 93 V. A. Boussiotis, *N. Engl. J. Med.*, 2016, **375**, 1767–1778.
- 94 W. Zou, J. D. Wolchok and L. Chen, *Sci. Transl. Med.*, 2016, **8**, 328rv324.
- 95 J. R. Brahmer, S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, H. C. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, S. Chen, T. M. Salay, S. Alaparthi, J. F. Grosso, A. J. Korman, S. M. Parker, S. Agrawal,



- S. M. Goldberg, D. M. Pardoll, A. Gupta and J. M. Wigginton, *N. Engl. J. Med.*, 2012, **366**, 2455–2465.
- 96 O. Hamid, C. Robert, A. Daud, F. S. Hodi, W. J. Hwu, R. Kefford, J. D. Wolchok, P. Hersey, R. W. Joseph, J. S. Weber, R. Dronca, T. C. Gangadhar, A. Patnaik, H. Zarour, A. M. Joshua, K. Gergich, J. Ellassaiss-Schaap, A. Algazi, C. Mateus, P. Boasberg, P. C. Tumeh, B. Chmielowski, S. W. Ebbinghaus, X. N. Li, S. P. Kang and A. Ribas, *N. Engl. J. Med.*, 2013, **369**, 134–144.
- 97 T. Powles, J. P. Eder, G. D. Fine, F. S. Braiteh, Y. Loriot, C. Cruz, J. Bellmunt, H. A. Burris, D. P. Petrylak, S. L. Teng, X. Shen, Z. Boyd, P. S. Hegde, D. S. Chen and N. J. Vogelzang, *Nature*, 2014, **515**, 558–562.
- 98 C. Robert, G. V. Long, B. Brady, C. Dutriaux, M. Maio, L. Mortier, J. C. Hassel, P. Rutkowski, C. McNeil, E. Kalinka-Warzocha, K. J. Savage, M. M. Hernberg, C. Lebbe, J. Charles, C. Mihalciou, V. Chiarion-Sileni, C. Mauch, F. Cognetti, A. Arance, H. Schmidt, D. Schadendorf, H. Gogas, L. Lundgren-Eriksson, C. Horak, B. Sharkey, I. M. Waxman, V. Atkinson and P. A. Ascierto, *N. Engl. J. Med.*, 2015, **372**, 320–330.
- 99 C. Boutros, A. Tarhini, E. Routier, O. Lambotte, F. L. Ladurie, F. Carbonnel, H. Izzeddine, A. Marabelle, S. Champiat, A. Berdelou, E. Lanoy, M. Texier, C. Libenciuc, A. M. Eggermont, J. C. Soria, C. Mateus and C. Robert, *Nat. Rev. Clin. Oncol.*, 2016, **13**, 473–486.
- 100 D. B. Johnson, J. M. Balko, M. L. Compton, S. Chalkias, J. Gorham, Y. Xu, M. Hicks, I. Puzanov, M. R. Alexander, T. L. Bloomer, J. R. Becker, D. A. Slosky, E. J. Phillips, M. A. Pilkinton, L. Craig-Owens, N. Kola, G. Plautz, D. S. Reshef, J. S. Deutsch, R. P. Deering, B. A. Olenchock, A. H. Lichtman, D. M. Roden, C. E. Seidman, I. J. Koralnik, J. G. Seidman, R. D. Hoffman, J. M. Taube, L. A. Diaz Jr., R. A. Anders, J. A. Sosman and J. J. Moslehi, *N. Engl. J. Med.*, 2016, **375**, 1749–1755.
- 101 L. Cassetta and J. W. Pollard, *Nat. Rev. Drug Discovery*, 2018, **17**, 887–904.
- 102 M. Xu, I. Mizoguchi, N. Morishima, Y. Chiba, J. Mizuguchi and T. Yoshimoto, *Clin. Dev. Immunol.*, 2010, **2010**, 832454.
- 103 S. Musetti and L. Huang, *ACS Nano*, 2018, **12**, 11740–11755.
- 104 D. A. Hume and K. P. MacDonald, *Blood*, 2012, **119**, 1810–1820.
- 105 X. Huang, J. Wu, M. He, X. Hou, Y. Wang, X. Cai, H. Xin, F. Gao and Y. Chen, *Mol. Pharmaceutics*, 2019, **16**, 2172–2183.
- 106 Z. Wang, X. Xue, Y. He, Z. Lu, B. Jia, H. Wu, Y. Yuan, Y. Huang, H. Wang, H. Lu, K. S. Lam, T.-Y. Lin and Y. Li, *Adv. Funct. Mater.*, 2018, **28**, 1802159.
- 107 W. Qing, X. Xing, D. Feng, R. Chen and Z. Liu, *Photodiagn. Photodyn. Ther.*, 2021, **36**, 102521.
- 108 Y. Kong, Y. Dai, D. Qi, W. Du, H. Ni, F. Zhang, H. Zhao, Q. Shen, M. Li and Q. Fan, *ACS Appl. Bio Mater.*, 2021, **4**, 7595–7604.
- 109 F. J. P. Costa, M. Nave, R. Lima-Sousa, C. G. Alves, B. L. Melo, I. J. Correia and D. de Melo-Diogo, *Int. J. Pharm.*, 2023, **635**, 122713.
- 110 S. Huang, Z. Ma, C. Sun, Q. Zhou, Z. Li, S. Wang, Q. Yan, C. Liu, B. Hou and C. Zhang, *J. Mater. Chem. B*, 2022, **10**, 2828–2843.
- 111 D. Y. Fan, Y. Tian and Z. J. Liu, *Front. Chem.*, 2019, **7**, 675.
- 112 Q. Chen, Y. Li, S. Zhou, D. Chen, M. Zhou, Q. Chen, Y. Lu, N. Cai, C. Liu, Y. Guo, Z. Qiu, X. Hou, J. Tu, W. Shen and C. Sun, *J. Controlled Release*, 2022, **350**, 803–814.
- 113 H. D. Han, C. K. Song, Y. S. Park, K. H. Noh, J. H. Kim, T. Hwang, T. W. Kim and B. C. Shin, *Int. J. Pharm.*, 2008, **350**, 27–34.
- 114 S. H. Seo, H. D. Han, K. H. Noh, T. W. Kim and S. W. Son, *Clin. Exp. Metastasis*, 2009, **26**, 179–187.
- 115 J. Gu, G. Zhao, J. Yu, P. Xu, J. Yan, Z. Jin, S. Chen, Y. Wang, L. W. Zhang and Y. Wang, *J. Nanobiotechnol.*, 2022, **20**, 372.
- 116 T. Wang, J. Zhang, T. Hou, X. Yin and N. Zhang, *Nanoscale*, 2019, **11**, 13934–13946.
- 117 Q. Lv, C. He, F. Quan, S. Yu and X. Chen, *Bioact. Mater.*, 2018, **3**, 118–128.
- 118 Z. Chen, Y. Rong, J. Ding, X. Cheng, X. Chen and C. He, *Pharmaceutics*, 2023, **15**, 428.
- 119 V. Akbari, E. Hejazi, M. Minaian, J. Emami, A. Lavasanifar and M. Rezazadeh, *J. Biomater. Appl.*, 2022, **37**, 551–562.
- 120 H. Jin, C. Wan, Z. Zou, G. Zhao, L. Zhang, Y. Geng, T. Chen, A. Huang, F. Jiang, J. P. Feng, J. F. Lovell, J. Chen, G. Wu and K. Yang, *ACS Nano*, 2018, **12**, 3295–3310.
- 121 D. D. Guo, S. H. Hong, H. L. Jiang, J. H. Kim, A. Minai-Tehrani, J. E. Kim, J. Y. Shin, T. Jiang, Y. K. Kim, Y. J. Choi, C. S. Cho and M. H. Cho, *Biomaterials*, 2012, **33**, 2272–2281.
- 122 Y. Brudno, E. A. Silva, C. J. Kearney, S. A. Lewin, A. Miller, K. D. Martinick, M. Aizenberg and D. J. Mooney, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 12722–12727.
- 123 J. Conde, N. Oliva, M. Atilano, H. S. Song and N. Artzi, *Nat. Mater.*, 2016, **15**, 353–363.
- 124 R. Liu, O. V. Khullar, A. P. Griset, J. E. Wade, K. A. V. Zubris, M. W. Grinstaff and Y. L. Colson, *Ann. Thorac. Surg.*, 2011, **91**, 1077–1084.
- 125 J. W. Nichols and Y. H. Bae, *J. Controlled Release*, 2014, **190**, 451–464.
- 126 D. Simberg, *ACS Nano*, 2015, **9**, 8647–8650.
- 127 C. von Roemeling, W. Jiang, C. K. Chan, I. L. Weissman and B. Y. S. Kim, *Trends Biotechnol.*, 2017, **35**, 159–171.
- 128 J. Wan, S. Geng, H. Zhao, X. Peng, Q. Zhou, H. Li, M. He, Y. Zhao, X. Yang and H. Xu, *J. Controlled Release*, 2016, **235**, 328–336.
- 129 K. Nguyen, P. N. Dang and E. Alsberg, *Acta Biomater.*, 2013, **9**, 4487–4495.
- 130 S. Wilhelm, A. J. Tavares, Q. Dai, S. Ohta, J. Audet, H. F. Dvorak and W. C. W. Chan, *Nat. Rev. Mater.*, 2016, **1**, 16014.
- 131 M. Kulkarni, U. Greiser, T. O'Brien and A. Pandit, *Trends Biotechnol.*, 2010, **28**, 28–36.
- 132 S. A. Bencherif, R. Warren Sands, O. A. Ali, W. A. Li, S. A. Lewin, T. M. Braschler, T. Y. Shih, C. S. Verbeke, D. Bhatta, G. Dranoff and D. J. Mooney, *Nat. Commun.*, 2015, **6**, 7556.



- 133 G. R. Shin, H. E. Kim, J. H. Kim, S. Choi and M. S. Kim, *Pharmaceutics*, 2021, **13**, 1953.
- 134 W. Wang, H. Song, J. Zhang, P. Li, C. Li, C. Wang, D. Kong and Q. Zhao, *J. Controlled Release*, 2015, **203**, 57–66.
- 135 X. Dai and C. Tan, *Adv. Drug Delivery Rev.*, 2015, **81**, 184–197.
- 136 H. Hu, Z. Lin, B. He, W. Dai, X. Wang, J. Wang, X. Zhang, H. Zhang and Q. Zhang, *J. Controlled Release*, 2015, **220**, 189–200.
- 137 L. E. Strong, S. N. Dahotre and J. L. West, *J. Controlled Release*, 2014, **178**, 63–68.
- 138 P. Huang, Y. Zhang, W. Wang, J. Zhou, Y. Sun, J. Liu, D. Kong, J. Liu and A. Dong, *J. Controlled Release*, 2015, **220**, 456–464.
- 139 A. Gilam, J. Conde, D. Weissglas-Volkov, N. Oliva, E. Friedman, N. Artzi and N. Shomron, *Nat. Commun.*, 2016, **7**, 12868.
- 140 M. Hamidi, A. Azadi and P. Rafiei, *Adv. Drug Delivery Rev.*, 2008, **60**, 1638–1649.
- 141 I. Younes and M. Rinaudo, *Mar. Drugs*, 2015, **13**, 1133–1174.
- 142 H. Ding, C. J. Zhao, X. Cui, Y. F. Gu, W. T. Jia, M. N. Rahaman, Y. Wang, W. H. Huang and C. Q. Zhang, *PLoS One*, 2014, **9**, e85472.
- 143 M. Fathi, M. Alami-Milani, M. H. Geranmayeh, J. Barar, H. Erfan-Niya and Y. Omid, *Int. J. Biol. Macromol.*, 2019, **128**, 957–964.
- 144 A. Ahsan, M. A. Farooq and A. Parveen, *ACS Omega*, 2020, **5**, 20450–20460.
- 145 X. Han, X. Meng, Z. Wu, Z. Wu and X. Qi, *Mater. Sci. Eng.: C*, 2018, **93**, 1064–1072.
- 146 A. A. H. Abdellatif, A. M. Mohammed, I. Saleem, M. Alsharidah, O. Al Rugaie, F. Ahmed and S. K. Osman, *Pharmaceutics*, 2022, **14**, 661.
- 147 X. Wu, C. He, Y. Wu, X. Chen and J. Cheng, *Adv. Funct. Mater.*, 2015, **25**, 6744–6755.
- 148 H. Wang, F. Song, Q. Chen, R. Hu, Z. Jiang, Y. Yang and B. Han, *J. Biomed. Mater. Res., Part A*, 2015, **103**, 3879–3885.
- 149 S. Belali, A. R. Karimi and M. Hadizadeh, *Int. J. Biol. Macromol.*, 2018, **110**, 437–448.
- 150 C.-H. Chen, C.-Y. Kuo, S.-H. Chen, S.-H. Mao, C.-Y. Chang, K. Shalumon and J.-P. Chen, *Int. J. Mol. Sci.*, 2018, **19**, 1373.
- 151 D. Prochowicz, A. Kornowicz and J. Lewinski, *Chem. Rev.*, 2017, **117**, 13461–13501.
- 152 I. V. Kolesnichenko and E. V. Anslyn, *Chem. Soc. Rev.*, 2017, **46**, 2385–2390.
- 153 B.-w. Liu, H. Zhou, S.-t. Zhou and J.-y. Yuan, *Eur. Polym. J.*, 2015, **65**, 63–81.
- 154 B. Schmidt and C. Barner-Kowollik, *Angew. Chem., Int. Ed.*, 2017, **56**, 8350–8369.
- 155 H. Kuang, H. He, Z. Zhang, Y. Qi, Z. Xie, X. Jing and Y. Huang, *J. Mater. Chem. B*, 2014, **2**, 659–667.
- 156 C. Fiorica, F. S. Palumbo, G. Pitarresi, R. Puleio, L. Condorelli, G. Collura and G. Giammona, *Int. J. Pharm.*, 2020, **589**, 119879.
- 157 C. Fu, X. Lin, J. Wang, X. Zheng, X. Li, Z. Lin and G. Lin, *J. Mater. Sci.: Mater. Med.*, 2016, **27**, 73.
- 158 M. Jorfi and E. J. Foster, *J. Appl. Polym. Sci.*, 2015, **132**, 41719.
- 159 B. Medronho, A. Romano, M. G. Miguel, L. Stigsson and B. Lindman, *Cellulose*, 2012, **19**, 581–587.
- 160 F. Joubert, O. M. Musa, D. R. Hodgson and N. R. Cameron, *Chem. Soc. Rev.*, 2014, **43**, 7217–7235.
- 161 F. Andrade, M. M. Roca-Melendres, M. Llaguno, D. Hide, I. Raurell, M. Martell, S. Vijayakumar, M. Oliva, S. Schwartz Jr., E. F. Duran-Lara, D. Rafael and I. Abasolo, *Carbohydr. Polym.*, 2022, **295**, 119859.
- 162 J. You, J. Cao, Y. Zhao, L. Zhang, J. Zhou and Y. Chen, *Biomacromolecules*, 2016, **17**, 2839–2848.
- 163 J. K. Kim, Y. W. Won, K. S. Lim, E. J. Park and Y. H. Kim, *J. Controlled Release*, 2011, **152**(Suppl 1), e44–e45.
- 164 L. Weng, N. Rostambeigi, N. D. Zantek, P. Rostamzadeh, M. Bravo, J. Carey and J. Golzarian, *Acta Biomater.*, 2013, **9**, 8182–8191.
- 165 L. Ding, Q. Wang, M. Shen, Y. Sun, X. Zhang, C. Huang, J. Chen, R. Li and Y. Duan, *Autophagy*, 2017, **13**, 1176–1190.
- 166 Y. Sheng, J. Gao, Z. Z. Yin, J. Kang and Y. Kong, *Carbohydr. Polym.*, 2021, **269**, 118325.
- 167 L. R. Balahura, S. Dinescu, M. Balas, A. Cernescu, A. Lungu, G. M. Vlasceanu, H. Iovu and M. Costache, *Pharmaceutics*, 2021, **13**, 1189.
- 168 S. R. Bollareddy, V. Krishna, G. Roy, D. Dasari, A. Dhar and V. V. K. Venuganti, *AAPS PharmSciTech*, 2022, **23**, 70.
- 169 X. Jiang, F. Zeng, X. Yang, C. Jian, L. Zhang, A. Yu and A. Lu, *Acta Biomater.*, 2022, **141**, 102–113.
- 170 N. S. V. Capanema, A. A. P. Mansur, S. M. Carvalho, I. C. Carvalho, P. Chagas, L. C. A. de Oliveira and H. S. Mansur, *Carbohydr. Polym.*, 2018, **195**, 401–412.
- 171 O. Vittorio, G. Cirillo, F. Iemma, G. Di Turi, E. Jacchetti, M. Curcio, S. Barbuti, N. Funel, O. I. Parisi, F. Puoci and N. Picci, *Pharm. Res.*, 2012, **29**, 2601–2614.
- 172 O. Vittorio, M. Brandl, G. Cirillo, K. Kimpton, E. Hinde, K. Gaus, E. Yee, N. Kumar, H. Duong, C. Fleming, M. Haber, M. Norris, C. Boyer and M. Kavallaris, *Oncotarget*, 2016, **7**, 47479–47493.
- 173 A. Agarwal, U. Gupta, A. Asthana and N. K. Jain, *Biomaterials*, 2009, **30**, 3588–3596.
- 174 L. Li, C. Wang, Q. Huang, J. Xiao, Q. Zhang and Y. Cheng, *J. Mater. Chem. B*, 2018, **6**, 2474–2480.
- 175 J. Deng, X. Xun, W. Zheng, Y. Su, L. Zheng, C. Wang and M. Su, *J. Mater. Chem. B*, 2018, **6**, 7966–7973.
- 176 F. Q. Luo, W. Xu, J. Y. Zhang, R. Liu, Y. C. Huang, C. Xiao and J. Z. Du, *Acta Biomater.*, 2022, **147**, 235–244.
- 177 S. Huang, H. Liu, S. Huang, T. Fu, W. Xue and R. Guo, *Carbohydr. Polym.*, 2020, **246**, 116650.
- 178 R. J. van Es, J. F. Nijsen, H. F. Dullens, M. Kicken, A. van der Bilt, W. Hennink, R. Koole and P. J. Slootweg, *J. Cranio-Maxillofac. Surg.*, 2001, **29**, 289–297.
- 179 S. O. Solomevich, P. M. Bychkovsky, T. L. Yurkshtovich, N. V. Golub, P. Y. Mirchuk, M. Y. Revtovich and A. I. Shmak, *Carbohydr. Polym.*, 2019, **226**, 115308.
- 180 M. R. Saboktakin, R. M. Tabatabaie, P. Ostovarazar, A. Maharramov and M. A. Ramazanov, *Int. J. Biol. Macromol.*, 2012, **51**, 544–549.



- 181 B. Balakrishnan and A. Jayakrishnan, *Biomaterials*, 2005, **26**, 3941–3951.
- 182 Y. Ikada and Y. Tabata, *Adv. Drug Delivery Rev.*, 1998, **31**, 287–301.
- 183 K. Kawai, S. Suzuki, Y. Tabata, Y. Ikada and Y. Nishimura, *Biomaterials*, 2000, **21**, 489–499.
- 184 M. Yamamoto, Y. Ikada and Y. Tabata, *J. Biomater. Sci., Polym. Ed.*, 2001, **12**, 77–88.
- 185 A. Gaowa, T. Horibe, M. Kohno, K. Sato, H. Harada, M. Hiraoka, Y. Tabata and K. Kawakami, *J. Controlled Release*, 2014, **176**, 1–7.
- 186 D. Ding, Z. Zhu, R. Li, X. Li, W. Wu, X. Jiang and B. Liu, *ACS Nano*, 2011, **5**, 2520–2534.
- 187 P. Li, W. Chen, Y. Yan, B. Chen, Y. Wang and X. Huang, *ACS Appl. Bio Mater.*, 2019, **2**, 3722–3729.
- 188 K. Yamashita, S. Tsunoda, S. Gunji, T. Murakami, T. Suzuki, Y. Tabata and Y. Sakai, *Surg. Today*, 2019, **49**, 785–794.
- 189 L. Liu, T. Sakaguchi, T. Kanda, J. Hitomi, Y. Tabata and K. Hatakeyama, *Cancer Chemother. Pharmacol.*, 2003, **51**, 53–57.
- 190 J. A. Burdick, *Biomed. Mater.*, 2012, **7**, 020201.
- 191 J. A. Burdick and G. D. Prestwich, *Adv. Mater.*, 2011, **23**, H41–H56.
- 192 S. Mitragotri, P. A. Burke and R. Langer, *Nat. Rev. Drug Discovery*, 2014, **13**, 655–672.
- 193 D. Seliktar, *Science*, 2012, **336**, 1124–1128.
- 194 Y. Y. Chen, H. C. Wu, J. S. Sun, G. C. Dong and T. W. Wang, *Langmuir*, 2013, **29**, 3721–3729.
- 195 H. J. Jhan, J. J. Liu, Y. C. Chen, D. Z. Liu, M. T. Sheu and H. O. Ho, *Nanomedicine*, 2015, **10**, 1263–1274.
- 196 M. T. Sheu, H. J. Jhan, C. Y. Su, L. C. Chen, C. E. Chang, D. Z. Liu and H. O. Ho, *Colloids Surf., B*, 2016, **143**, 260–270.
- 197 J. Wroblewska-Krepsztul, T. Rydzkowski, I. Michalska-Pozoga and V. K. Thakur, *Nanomaterials*, 2019, **9**, 404.
- 198 J.-S. Yang, Y.-J. Xie and W. He, *Carbohydr. Polym.*, 2011, **84**, 33–39.
- 199 C. Wang, X. Wang, K. Dong, J. Luo, Q. Zhang and Y. Cheng, *Biomaterials*, 2016, **104**, 129–137.
- 200 M. Liu, X. Song, Y. Wen, J. L. Zhu and J. Li, *ACS Appl. Mater. Interfaces*, 2017, **9**, 35673–35682.
- 201 M. J. Chalanqui, S. Pentlavalli, C. McCrudden, P. Chambers, M. Ziminska, N. Dunne and H. O. McCarthy, *Mater. Sci. Eng., C*, 2019, **95**, 409–421.
- 202 B. Yavari, R. Mahjub, M. Saidijam, M. Raigani and M. Soleimani, *Curr. Protein Pept. Sci.*, 2018, **19**, 759–770.
- 203 Y. Song, Y. Ding and C. M. Dong, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2022, **14**, e1742.
- 204 Y. Wan, W. Dai, R. J. Nevagi, I. Toth and P. M. Moyle, *Acta Biomater.*, 2017, **59**, 257–268.
- 205 S. Dissanayake, W. A. Denny, S. Gamage and V. Sarojini, *J. Controlled Release*, 2017, **250**, 62–76.
- 206 T. Samec, J. Boulos, S. Gilmore, A. Hazelton and A. Alexander-Bryant, *Mater. Today Bio*, 2022, **14**, 100248.
- 207 J. Xu, G. Qi, W. Wang and X. S. Sun, *npj Sci. Food*, 2021, **5**, 14.
- 208 X. Ren, N. Wang, Y. Zhou, A. Song, G. Jin, Z. Li and Y. Luan, *Acta Biomater.*, 2021, **124**, 179–190.
- 209 R. Jin, J. Yang, D. Zhao, X. Hou, C. Li, W. Chen, Y. Zhao, Z. Yin and B. Liu, *J. Nanobiotechnol.*, 2019, **17**, 99.
- 210 M. C. Garrett, T. M. O'Shea, A. L. Wollenberg, A. M. Bernstein, D. Hung, B. Staarman, H. Soto, T. J. Deming, M. V. Sofroniew and H. I. Kornblum, *PLoS One*, 2020, **15**, e0219632.
- 211 M. Liu, Z. Cao, R. Zhang, Y. Chen and X. Yang, *ACS Appl. Mater. Interfaces*, 2021, **13**, 33874–33884.
- 212 H. Song, P. Huang, J. Niu, G. Shi, C. Zhang, D. Kong and W. Wang, *Biomaterials*, 2018, **159**, 119–129.
- 213 X. L. Hou, X. Dai, J. Yang, B. Zhang, D. H. Zhao, C. Q. Li, Z. Y. Yin, Y. D. Zhao and B. Liu, *J. Mater. Chem. B*, 2020, **8**, 8623–8633.
- 214 R. Jin, X. Yang, D. Zhao, X. Hou, C. Li, X. Song, W. Chen, Q. Wang, Y. Zhao and B. Liu, *Nanoscale*, 2019, **11**, 16080–16091.
- 215 J. Liu, Y. Zhang, Q. Li, Z. Feng, P. Huang, W. Wang and J. Liu, *Acta Biomater.*, 2020, **114**, 133–145.
- 216 Y. Shi, D. Li, C. He and X. Chen, *Macromol. Biosci.*, 2021, **21**, e2100049.
- 217 R. Jin, J. Yang, P. Ding, C. Li, B. Zhang, W. Chen, Y. D. Zhao, Y. Cao and B. Liu, *Nanotechnology*, 2020, **31**, 205102.
- 218 A. R. Karimi, A. Khodadadi and M. Hadizadeh, *RSC Adv.*, 2016, **6**, 91445–91452.
- 219 W. Zhang, X. Jin, H. Li, R. R. Zhang and C. W. Wu, *Carbohydr. Polym.*, 2018, **186**, 82–90.
- 220 A. Lopez-Noriega, C. L. Hastings, B. Ozbakir, K. E. O'Donnell, F. J. O'Brien, G. Storm, W. E. Hennink, G. P. Duffy and E. Ruiz-Hernandez, *Adv. Healthcare Mater.*, 2014, **3**, 854–859.
- 221 L. Saeednia, L. Yao, K. Cluff and R. Asmatulu, *ACS Omega*, 2019, **4**, 4040–4048.
- 222 F.-Y. J. Huang, G.-Y. Gan, W.-Y. Lin, L.-K. Huang, T.-Y. Luo, J.-J. Hong and B.-T. Hsieh, *J. Radioanal. Nucl. Chem.*, 2013, **299**, 31–40.
- 223 Y. Liang, X. Zhao, P. X. Ma, B. Guo, Y. Du and X. Han, *J. Colloid Interface Sci.*, 2019, **536**, 224–234.
- 224 Y. Zhao, H. Yan, S. Qiao, L. Zhang, T. Wang, Q. Meng, X. Chen, F. H. Lin, K. Guo, C. Li and W. Tian, *J. Mater. Chem. B*, 2016, **4**, 6183–6191.
- 225 X. Chen and Z. Liu, *Macromol. Rapid Commun.*, 2016, **37**, 1533–1539.
- 226 K. Xu, F. Lee, S. J. Gao, J. E. Chung, H. Yano and M. Kurisawa, *J. Controlled Release*, 2013, **166**, 203–210.
- 227 X. Chen, Z. Liu, S. G. Parker, X. Zhang, J. J. Gooding, Y. Ru, Y. Liu and Y. Zhou, *ACS Appl. Mater. Interfaces*, 2016, **8**, 15857–15863.
- 228 A. Ranga, M. P. Lutolf, J. Hilborn and D. A. Ossipov, *Biomacromolecules*, 2016, **17**, 1553–1560.
- 229 P. Davoodi, W. C. Ng, M. P. Srinivasan and C. H. Wang, *Biotechnol. Bioeng.*, 2017, **114**, 2931–2946.
- 230 P. Davoodi, W. C. Ng, W. C. Yan, M. P. Srinivasan and C. H. Wang, *ACS Appl. Mater. Interfaces*, 2016, **8**, 22785–22800.



- 231 C. Xing, S. Chen, M. Qiu, X. Liang, Q. Liu, Q. Zou, Z. Li, Z. Xie, D. Wang, B. Dong, L. Liu, D. Fan and H. Zhang, *Adv. Healthcare Mater.*, 2018, **7**, e1701510.
- 232 S. GuhaSarkar, P. More and R. Banerjee, *J. Controlled Release*, 2017, **245**, 147–156.
- 233 Y. Zheng, Y. Liang, D. Zhang, Z. Zhou, J. Li, X. Sun and Y. N. Liu, *Chem. Commun.*, 2018, **54**, 13805–13808.
- 234 X. Niu, Z. Zhang and Y. Zhong, *Mater. Sci. Eng., C*, 2017, **77**, 888–894.
- 235 P. Lee, C. N. Lok, C. M. Che and W. J. Kao, *Pharm. Res.*, 2019, **36**, 61.
- 236 R. Oun, J. A. Plumb and N. J. Wheate, *J. Inorg. Biochem.*, 2014, **134**, 100–105.
- 237 T. Takei, K. Sugihara, M. Yoshida and K. Kawakami, *J. Biomater. Sci., Polym. Ed.*, 2013, **24**, 1333–1342.
- 238 E. Oh, J. E. Oh, J. Hong, Y. Chung, Y. Lee, K. D. Park, S. Kim and C. O. Yun, *J. Controlled Release*, 2017, **259**, 115–127.
- 239 V. Castelletto, C. J. C. Edwards-Gayle, F. Greco, I. W. Hamley, J. Seitsonen and J. Ruokolainen, *ACS Appl. Mater. Interfaces*, 2019, **11**, 33573–33580.
- 240 T. Kerdsirichairat, A. K. Narang, E. Thompson, S. H. Kim, A. Rao, K. Ding and E. J. Shin, *Gastroenterology*, 2019, **157**, 933–935.
- 241 G. Milcovich, S. Lettieri, F. E. Antunes, B. Medronho, A. C. Fonseca, J. F. J. Coelho, P. Marizza, F. Perrone, R. Farra, B. Dapas, G. Grassi, M. Grassi and S. Giordani, *Adv. Colloid Interface Sci.*, 2017, **249**, 163–180.
- 242 A. Sood, A. Dev, S. S. Das, H. J. Kim, A. Kumar, V. K. Thakur and S. S. Han, *Int. J. Biol. Macromol.*, 2023, **232**, 123283.
- 243 Y. Tu, N. Chen, C. Li, H. Liu, R. Zhu, S. Chen, Q. Xiao, J. Liu, S. Ramakrishna and L. He, *Acta Biomater.*, 2019, **90**, 1–20.
- 244 A. Salis, G. Rassu, M. Budai-Szucs, I. Benzoni, E. Csanyi, S. Berko, M. Maestri, P. Dionigi, E. P. Porcu, E. Gavini and P. Giunchedi, *Expert Opin. Drug Delivery*, 2015, **12**, 1583–1596.
- 245 J. I. Pesa, M. J. Rico, V. R. Rozados, O. G. Scharovsky, J. A. Luna and L. N. Mengatto, *J. Pharm. Pharmacol.*, 2018, **70**, 1494–1502.
- 246 S. Ren, Y. Dai, C. Li, Z. Qiu, X. Wang, F. Tian, S. Zhou, Q. Liu, H. Xing, Y. Lu, X. Chen and N. Li, *Eur. J. Pharm. Sci.*, 2016, **92**, 137–145.
- 247 D. Guo, S. Xu, Y. Huang, H. Jiang, W. Yasen, N. Wang, Y. Su, J. Qian, J. Li, C. Zhang and X. Zhu, *Biomaterials*, 2018, **177**, 67–77.
- 248 H. Kang, H. Liu, X. Zhang, J. Yan, Z. Zhu, L. Peng, H. Yang, Y. Kim and W. Tan, *Langmuir*, 2011, **27**, 399–408.
- 249 R. Y. Tam, L. J. Smith and M. S. Shoichet, *Acc. Chem. Res.*, 2017, **50**, 703–713.

